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ABSTRACT 
 
Classical coeliac disease (CD) is a well-defined syndrome of small bowel 
villous atrophy associated with abdominal pain, malabsorption, and weight 
loss as a result of gluten-sensitivity, reversed rapidly by gluten exclusion diet. 
'LVHDVH DVVRFLDWLRQV LQFOXGH GHUPDWLWLV KHUSHWLIRUPLV '+ $GGLVRQ¶V
disease, type 1 diabetes mellitus, autoimmune thyroid disease and a variety of 
neurological disorders. This thesis aims to investigate the hypothesis of the 
existence of a gluten sensitive neurological disease 
 
CD with coexistent neurological dysfunction is only rarely reported in a 
neurological setting. 23 cases were reported from the British Neurological 
Surveillance Unit (BNSU) over 24 months and 13 locally over 31 months. 18 
sets of notes (50%) were reviewed. These patients comprise a heterogeneous 
group of neurological disorders including epilepsy, myelopathy, axonal 
neuropathy and migraine.  
 
Neurological disorders in patients with confirmed gluten sensitivity may occur 
simply by chance. In a cohort of 801 CD patients, 54 neurological disorders 
were identified in 177 patients including stroke (2.9%), migraine (2.7%), 
epilepsy (2.6%) and carpal tunnel syndrome (2.0%).  
 
More detailed investigation of 35 patients with DH and 53 patients with CD, 
confirmed a low prevalence of idiopathic neurological abnormalities (DH 11%; 
CD 25%).  Analysis of sera from these patients did not identify the presence of 
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anti-neuronal antibodies. A novel anti-spinal antibody was identified in over 
50% of the subjects with DH but this requires further characterisation.  
 
It has been postulated that patients with idiopathic neurological disease and 
anti-gliadin antibody (AGA) seropositivity are gluten sensitive. However, AGA 
lacks disease specificity being found in 10% of healthy blood donors. 
Screening of 49 unselected multiple sclerosis cases found IgG AGA in 12% of 
patients and 13% of blood donors confirming that AGA (especially IgG 
isotype) can be a non-specific finding. 
 
AGA, other food antibodies and tissue transglutaminase antibody (TTG) were 
measured in patients with idiopathic ataxia (20), hereditary ataxia (7) and 
idiopathic peripheral neuropathy (32). None of the cases was positive for IgA 
TTG making occult CD unlikely. Cerebellar ataxia with positive AGA (so-called 
µJOXWHQDWD[LD¶ZDV rare (4 cases in 2 years from a population of 2 million). All 
IRRG DQWLERGLHV WHVWHG $*$ KHQ¶V HJJ DOEXPHQ DQG FRZ¶V PLON
lactoglobulin), particularly IgG, were a common finding in both ataxia and 
peripheral neuropathy groups.  
 
This study found no evidence for gluten neurotoxicity. Serological tests, 
particularly AGA, need to be interpreted with caution. Further study is required 
regarding the nature of the association between neurological illness and 
gluten sensitivity. 
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Chapter 1 ± Introduction 
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1.1 Aims 
This thesis aims to further elucidate the association between gluten 
sensitivity and neurological disorders. This will be achieved by the following 
means:  
1. Summary of the literature on this topic in terms of epidemiology, 
pathogenesis and complications of known gluten sensitive disease namely 
coeliac disease (CD) and dermatitis herpetiformis (DH), as well as review 
of the evidence for the existence of gluten sensitive neurological 
syndromes 
2. Detailed case report analysis of patients with co-existent neurological 
dysfunction and CD 
3. Study of the features and prevalence of neurological abnormalities in 
patients with confirmed gluten sensitivity (CD and DH) 
4. Study of the prevalence of gluten sensitivity in patients with specific 
neurological abnormalities namely idiopathic peripheral neuropathy, 
idiopathic ataxia and multiple sclerosis  
5. Immune profiles and genetic analysis of patients with neurological 
dysfunction and CD. 
 
1.2 Background - Coeliac disease 
Dicke (Dicke 1950) first demonstrated the harmful effect of gluten ingestion in 
patients with coeliac disease (CD). Classically CD is known to be a chronic 
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inflammatory disease of the small bowel mucosa associated with 
malabsorption, steatorrhoea and weight loss as a result of sensitivity to gluten. 
Gluten is found in foods containing wheat, barley and rye. The treatment i.e. 
strict gluten-free diet (GFD) results not only in symptomatic improvement but 
also restoration of normal mucosal architecture. Furthermore, re-introduction 
of gluten results in symptomatic and histological relapse. Although biopsy of 
VPDOO ERZHO UHPDLQV WKH GLDJQRVWLF ³JROG VWDQGDUG´ IRU&' DQWLERG\ WHVWLQJ
can be a useful supplementary investigation. 
 
1.3 Epidemiology 
Ideas about the incidence and prevalence of CD have changed greatly. For 
reasons which are not completely understood, adult incidence rates have 
increased (Jenkins, Hawkes et al. 1998; Hawkes, Swift et al. 2000). 
Furthermore, population screening studies have shown that CD remains 
underdiagnosed in adults (Unsworth and Brown 1994; Hin, Bird et al. 1999). 
CD is mainly found in Western European populations and countries where 
Europeans have migrated. Prevalence rates estimated from population 
screening are as high as 1:82 in adults in New Zealand (Cook, Burt et al. 
2000), and 1.3% in healthy Swedish children (Carlsson, Axelsson et al. 2001). 
The variable prevalence rates amongst different populations may be 
explained by genetic factors. However, interpretation of epidemiological data 
is complicated because of variations in disease definition and case 
ascertainment. One study has shown a three-fold increase in diagnosis rate in 
a hospital with a special interest compared to two other hospitals (Swinson 
and Levi 1980). 
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CD was once thought to be a childhood illness typically presenting with 
malnutrition and abdominal symptoms but is now recognised as a condition 
affecting all ages that can also present with atypical and often subtle 
symptoms. Reasons proposed for this have included altered dietary habits 
such as increased breast-feeding and longer time to weaning to solids 
(Ivarsson, Hernell et al. 2002). Most adult patients have mild symptoms that 
on direct questioning would be compatible with a diagnosis of CD. They may 
present with non-specific or trivial complaints and the diagnosis is only 
suspected from abnormalities found in routine blood tests such as anaemia or 
from the results of specific serological tests.  
1.3.1 Changing pattern of coeliac disease-The Coeliac Iceberg 
Some asymptomatic patients with an enteropathy characteristic of CD are 
ODEHOOHG³VLOHQW&'´ZKLOHRWKHUSDWLHQWVZKRKDYHDQDSSDUHQWO\QRUPDOVPDOO
bowel biopsy but develop typical histological features later in life are regarded 
DV KDYLQJ ³ODWHQW &'´ 7KHVH REVHUYDWLRQV KDYH OHG WR WKH FRQFHSW RI D
³FRHOLDF LFHEHUJ´ PDGH up of a visible part of those who are diagnosed 
clinically and a far larger submerged portion that includes all individuals who 
are undiagnosed because of asymptomatic, occult or latent disease (Catassi, 
Ratsch et al. 1994).  This rise in diagnosis rate may not represent actual 
change in incidence because the advent of serological markers has changed 
our diagnostic ability, resulting in CD becoming more commonly recognised. 
The implications of this improved diagnostic rate, particularly in the less 
severely affected, remain unclear.  
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1.4 Pathogenesis 
The pathogenesis of CD as an autoimmune condition is multifactorial with a 
combination of genetic predisposition and environmental influences resulting 
in tissue injury caused by auto-reactive T cells or antibodies. This process is 
not completely understood but current evidence suggests that the disease is 
triggered by an external antigen, gluten, in a genetically susceptible individual. 
The disease appears to be specific to humans and thus satisfactory animal 
models have made pathophysiological research difficult.  
1.4.1 Genetic factors 
A major genetic role is implied by the occurrence of multiple cases within the 
same family (Auricchio, Greco et al. 1988) with studies of first degree relatives 
having as many as 10% with the disease (Hogberg, Falth-Magnusson et al. 
2003). Twin concordance is as high as 75% in monozygotic twins (Greco, 
Romino et al. 2002). However the 25% discordance in monozygotic twins 
implies a significant contribution by environmental factors.  
The main component of genetic predisposition lies in the major 
histocompatibility complex (MHC), a collection of genes on chromosome 6 
that encodes the human leucocyte antigens (HLA). HLA are cell surface 
glycoproteins (found on the surface of B cells, monocytes, activated T cells 
and enterocytes) that bind short peptides degraded or generated by the cell 
and present these antigens to CD4+ T helper cells. The role of MHC through 
molecular mimicry has been proposed as a possible mechanism for 
development of autoimmune disease that combines the influence of genetics 
and the environment. Alternatively, the HLA DQ molecule may select in the 
thymus for specific T cell receptors involved in the pathogenesis of CD. 
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Gliadin-specific T-cells in the small intenstines of coeliac patients use HLA 
DQ2 in antigen recognition to mount an inflammatory response (Lundin 2002). 
HLA Class II molecules are estimated to account for approximately 40% of the 
genetic load (Bevan, Popat et al. 1999). Greco et al (Greco, Romino et al. 
2002) showed substantial evidence that the very strong genetic component in 
CD is only partially due to the HLA region by looking at the genetic load in CD 
and estimating the concordance rate for the disease among twin pairs in a 
large population based study adjusting for HLA haplotype.   
More than 95% of patients with defined gluten sensitive disease i.e. CD and 
DH, carry the HLA DQ2 or DQ8 haplotype (Zubillaga, Vidales et al. 2002). The 
prevalence of these HLA haplotypes varies enormously in different ethnic 
groups but in the UK population is estimated at 40%. They are therefore 
common haplotypes in Caucasian populations and other factors must exist for 
development of gluten sensitivity as the majority of people with this haplotype 
will not develop CD despite gluten ingestion. 
1.4.2 Environmental factors 
CD is exacerbated by ingestion of foods containing wheat, rye, and barley. 
Toxic fragments in these cereals are rich in proline and glutamine and are 
collectively known as prolamins. The active prolamin fractions in each of these 
cereals are gliadin in wheat, secalin in rye and hordein in barley. In oats the 
prolamin fraction, avenin, is small, only 5-15%, which may account for 
tolerance of oats in the diets of some CD sufferers. Studies have shown that 
oats are probably not harmful and therefore an acceptable alternative in a 
GFD (Janatuinen, Kemppainen et al. 2002). 
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Most studies have focussed on wheat due to its nutritional importance. 
Fractionation of wheat produces a starch fraction and a protein fraction, 
gluten, of which gliadin is the soluble component. Gliadin accounts for 50% of 
wheat protein and within a single wheat fraction, there are approximately 45 
JOLDGLQV ZKLFK DUH VXEGLYLGHG LQWR Įȕ ȖDQG Ȧ VXEIUDFWLRQV GHSHQGLQJ RQ
their electrophoretic mobility. The amino acid sequence has been determined 
in the A-gliadin molecule and a number of in vitro studies and in vivo studies 
have indicated the presence of one or more CD activating epitopes on this 
molecule (Ciclitira 2003). A recent study showed that a peptide corresponding 
to residues 56- RI Į-gliadin exacerbates CD in vivo (Fraser, Engel et al. 
2003). 
 
It has been suggested that infection with adenovirus 12 sensitises the 
genetically predisposed host to A-gliadin by molecular mimicry resulting in 
gluten sensitive enteropathy (Kagnoff, Paterson et al. 1987). The E1b protein 
of adenovirus 12 has been reported to share a similar amino acid sequence to 
A-gliadin.  
1.4.3 Immunological factors 
The intestinal response in CD is triggered by gluten resulting in activation of 
macrophages, plasma cell recruitment, release of inflammatory cytokines and 
CD8 T lymphocyte infiltration. Although plasma cells produce antibodies to 
gliadin and connective tissue autoantigens, the intestinal damage is a cellular 
rather than humoral process. Indeed, Webster and co-authors showed that 
CD occurred in a hypogammaglobulinaemic patient suggesting that these 
  24 
antibodies are not crucial to pathogenesis (Webster, Slavin et al. 1981). They 
were unable to demonstrate specific cellular immunity to a subfraction of 
gluten implying that immunological reactions have a much less clear role in 
the pathogenesis of CD than previously thought. 
 
1.5 Recognised associations of coeliac disease 
Gluten intolerance can be considered a spectrum of conditions ranging from 
frank CD to latent CD and including extra-intestinal gluten intolerance and 
non-coeliac gastrointestinal gluten intolerance such as that seen in irritable 
bowel syndrome. Patients with a genetic susceptibility to gluten may have no 
intestinal abnormalities on small bowel biopsy. The precise mechanism for the 
activation of gut inflammation by gluten is not known although it is presumed 
to be immunological. Immune mechanisms such as the deposition of 
circulating immune complexes in other organs are also thought to cause the 
extra-intestinal manifestations of gluten sensitivity.  
 
Dermatitis herpetiformis (DH), characterised by IgA deposition in the papillary 
dermis, is a blistering skin condition (Figure 1.1) that exemplifies an extra-
LQWHVWLQDOPDQLIHVWDWLRQRIJOXWHQVHQVLWLYLW\7KH³JROGVWDQGDUG´IRUGLDJQRVLV
of DH remains skin biopsy. There is immuno-pathological and genetic data 
that DH and CD are closely related conditions on the basis of treatment 
response, common HLA, twin studies and autoantibody profiles.  CD and DH 
share the same strong association with the HLA DQ2 haplotype, presence of 
characteristic small intestinal changes and a similar rate of disease 
associations e.g. Type 1 Diabetes Mellitus. 
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Figure 1.1 Blisters on the elbows of a patient with dermatitis herpetiformis 
 
It has been suggested that CD is associated with conditions such as 
$GGLVRQ¶V Gisease (O'Leary, Walsh et al. 2002), Type I Diabetes Mellitus 
(Holmes 2001) and autoimmune thyroid disease (Sategna-Guidetti, Volta et 
al. 2001). A similar association has been proposed with other autoimmune 
conditions such as primary biliary cirrhosis (Sorensen, Thulstrup et al. 1999) 
DQG6MRJUHQ¶VV\QGURPH(Iltanen, Collin et al. 1999).  
The association of CD with a variety of neurological disorders has also been 
frequently described but whether a specific neurological association occurs 
with CD remains unproven. The basis of these associations is unclear. A 
genetic mechanism has been postulated. However, as CD is relatively 
common these may be chance findings.  This is discussed in more detail in 
Chapter 2. 
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1.6 Diagnosis  
1.6.1 Serological testing  
Improved screening for antibodies associated with CD i.e. antireticulin 
antibodies (ARA), IgA and IgG antigliadin antibodies (AGA), endomysial 
antibodies (EMA), anti-jejunal antibody (AJA) and tissue transglutaminase 
antibodies (TTG), has dramatically increased the numbers of diagnoses of CD 
in recent years. However, these antibodies have varying specificities and 
sensitivities, particularly when applied to population screening, and it is 
generally recognised that IgA ARA, AEA and TTG have heightened specificity 
when compared to AGA (Lagerqvist, Ivarsson et al. 2001).  
 
The presence of positive coeliac antibodies with normal small bowel 
architecture remains problematic. Follow-up of patients with normal small 
bowel architecture and positive coeliac antibodies has shown that positive 
ARA is a good predictor for later development of the disease when compared 
to AGA particularly the IgG subclass of AGA (Collin, Helin et al. 1993). In GSE 
the positive predictive value of isolated IgG AGA positivity and an initially 
normal small bowel biopsy is 0 %. In a further study the positive predictive 
value of EMA was 100% compared to only 28% for IgA AGA (Valdimarsson, 
Franzen et al. 1996).  
 
The available evidence from absorption and other studies suggests that ARA, 
EMA, AJA and TTG are one and the same. All four are believed to be 
antibodies to the same enzyme, tissue trans-glutaminase, simply giving 
different appearances when tested on different tissue substrates e.g. monkey 
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oesophagus and human foetal jejunum (AEA and AJA respectively). These 
autoantibodies are unique because they are predictably invoked in susceptible 
patients (CD) by an environmental agent, namely gluten, disappearing within 
several months of a strict GFD and reappearing following gluten challenge. 
AGA on the other hand is an anti-wheat protein antibody, which, like other 
simple food antibodies e.g. anti-ovalbumin and anti-casein, is extremely 
disease non-specific, particularly when of IgG isotype.  
1.6.2 Small bowel biopsy 
Small bowel biopsy is the only definitive test for CD and shows characteristic 
subtotal or total villous atrophy and crypt hypertrophy (Figure 1.2). There is 
evidence of an inflammatory cell infiltrate in the mucosa which in the 
epithelium consists almost exclusively of intra-epithelial lymphocytes (IEL) and 
in the lamina propria consists of plasma cells, lymphocytes and macrophages. 
There are degrees of severity of small intestinal lesions ranging from a 
VWUXFWXUDOO\ QRUPDO PXFRVD ZLWK LQFUHDVHG GHQVLW\ RI ,(/V H[SUHVVLQJ Ȗį 7
cell receptors (Grade 1) to irreversible atrophy seen in jejunoileitis and 
µ(QWHURSDWK\-Associated T-cell Lymphoma (EATCL).  
 
The Marsh classification is used to describe the range of abnormalities seen 
in the mucosa of patients with CD (Marsh 1992). Marsh Type I lesions have 
normal mucosal architecture with a lymphocytic infiltration of the villous 
epithelial layer. An IEL count over 30-40 per 100 enterocytes is arbitrarily 
used as a threshold denoting a significant increase.  In a Marsh Type II lesion, 
in addition to these findings, crypt hyperplasia and increased mitotic activity 
can be seen.  Marsh Type III lesions are characterised by villous atrophy 
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ranging from partial (IIIA), subtotal (IIIB) and total (IIIC) as described by 
Oberhuber and colleagues (Oberhuber, Granditsch et al. 1999). Marsh type IV 
lesions are rare and are seen in refractory CD.  
 
Whilst recognising that patients with so-FDOOHGµODWHQW&'¶GRH[LVWWKLVLVRQO\
rarely described and even in DH where 90% of patients do not have 
gastrointestinal symptoms, they are all said to have gluten-sensitive 
enteropathy (Reunala 1998). A flat small bowel mucosa can occur in 
numerous other conditions such as gastroenteritis, WURSLFDOVSUXHFRZ¶VPLON
intolerance and immunodeficiency syndromes. 
 
 
(a)                                     (b) 
Figure 1.2 Appearance of small bowel mucosa using light microscopy (a) 
flattened mucosa in a patient with untreated coeliac disease. (b) normal 
mucosa showing digitate villi 
 
1.7 Complications 
Reported complications of CD include malignancy, ulcerative jejunitis, 
disorders of bone metabolism, reduced fertility and splenic atrophy. The 
overall increased mortality in CD is estimated at twice that of the general 
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population (Logan, Rifkind et al. 1989) and this is mainly attributable to 
malignancy. Besides lymphoma patients are also at greater risk of 
oesophageal and small intestinal carcinoma. One study by Holmes et al 
(Holmes, Prior et al. 1989) found a two-fold increase of CD patients in 
developing cancer. There is evidence to suggest that overall cancer risk 
reduces to near normal after 5 years on a GFD hence the emphasis on early 
diagnosis and treatment. A recent review suggests that the magnitude of the 
incidence of malignant complications was over-estimated although there is a 
definite increased risk of Non-Hodgkins lymphoma of any site, particularly 
EATCL (Catassi, Bearzi et al. 2005). 
 
1.8 Treatment  
The mainstay of treatment of CD is lifelong exclusion of gluten-containing 
cereals in the diet. Appropriate dietary counselling is essential particularly if 
gluten-rich products (bread and pasta) are significant dietary staples. 
Furthermore, patients need to be warned regarding foods in which gluten may 
QRW EH DQ REYLRXV FRQVWLWXHQW HJ VDXFHV µKLGGHQ JOXWHQ¶ LQDGHTXDWHO\
labelled food and food contamination. Compliance is extremely variable with 
study figures ranging from 45 to 94%. There are many reasons for this 
including cost (although in Britain, CD patients should receive staple gluten 
free products on prescription), restrictions on lifestyle, peer pressure 
particularly amongst adolescents and finally, non-perceived benefit in patients 
with silent disease. Serum AGA is a useful measure of compliance as this 
reduces to normal within a few months of GFD.  
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The majority of paediatric patients respond well to a GFD whereas 10-15% of 
adult patients do not. There is a role for restricting either dairy products or 
other food products for a short period. There may be ongoing symptoms from 
severe damage of small intestinal enterocytes resulting in disaccharide 
deficiency for example. In a small minority of patients, immunosuppressants 
may become necessary such as steroids or even cyclophosphamide and 
azathioprine. 
 
It is recommended that patients with CD should have lifelong medical follow-
up to assess weight, routine blood indices and to address any health concerns 
that may arise particularly any new symptoms, diarrhoea or weight loss that 
may suggest a malignant complication. 
 
1.9 Discussion 
There is greater recognition that CD is increasingly prevalent worldwide 
largely as a result of improved serological screening and the widespread use 
of fibreoptic endoscopy to obtain small bowel biopsies. Although there are 
numerous well-recognised manifestations of CD, gastrointestinal features are 
the best recognised. Numerous other associations have been frequently 
GHVFULEHG LQFOXGLQJ QHXURORJLFDO GLVRUGHUV $GGLVRQ¶V GLVHDVH DQG
hypothyroidism, however the association of CD with these conditions is 
unclear. Whether a specific neurological complication occurs in CD, apart 
from those secondary to malabsorption, remains unproven. It has been 
suggested that patients with a variety of idiopathic neurological conditions 
should be screened for CD. Among this group even those patients without 
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overt CD may have positive antigliadin antibodies (AGA) and HLA profile 
characteristic of CD (Hadjivassiliou, Grunewald et al. 1998).  
The definition of disease mechanisms of complex inflammatory disorders is 
difficult with extensive interactions between genetic and environmental 
factors. CD, the prototypical disease of gluten sensitivity, is no exception. 
However with CD, key genetic and environmental factors have been identified. 
We have some understanding of predisposing HLA molecules, antigenic 
epitopes and disease-relevant T-lymphocytes. The main aim of this thesis was 
to gain a further understanding of the association of CD and neurological 
disease. CD is still not fully understood and research continues into its 
genetics, pathogenesis, epidemiology and immunology amongst others. Such 
comprehensive insight was clearly not within the constraints of this thesis but I 
will attempt to address some important misconceptions with regards to 
spectrum of neurological association, prevalence and serological screening.  
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Chapter 2 ± Neurological associations 
of Coeliac Disease 
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2.1 Aim 
This chapter aims to summarise the known literature on neurological 
associations of CD including possible aetiology, pathological findings and 
treatment potential. This is a comprehensive literature review performed by 
searching PubMed for articles written up to the end of 2006. 
2.2 Introduction 
The putative association of CD with neurological disorders has attracted much 
interest in recent years, the most frequent being epilepsy, cerebellar ataxia, 
peripheral neuropathy, dementia and depression. However the nature and 
mechanism of this association remains unclear.  
 
The first detailed descriptive study of patients with CD (confirmed on jejunal 
biopsy) and a neurological deficit was published by Cooke and Smith in 1966 
(Cooke and Smith 1966). They described a group of 16 patients with a variety 
of neurological findings. The predominant abnormality was a sensory ataxia 
suggesting damage to the dorsal columns in the spinal cord. These patients 
deteriorated despite dietary gluten restriction. Three patients had evidence of 
cerebellar dysfunction. Post-mortem study of 9 of these patients demonstrated 
spongiform changes in the lateral and posterior columns. 
 
Since then many different neurological disorders have been described in 
association with CD ranging from the relatively common like epilepsy, 
neuropathy and migraine to rarer associations such as chorea (Pereira, 
Edwards et al. 2004) and leukoencephalopathy (Beyenburg, Scheid et al. 
1998). 
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2.3 Neurological disturbances described with coeliac disease 
2.3.1 Epilepsy 
An increased prevalence of epilepsy in patients with CD has been proposed 
(Chapman, Laidlow et al. 1978). In addition, a high prevalence of CD has 
been seen in patients with bilateral occipital calcification (Ventura, Bouquet et 
al. 1991; Magaudda, Dalla Bernardina et al. 1993; Lea, Harbord et al. 1995), 
mainly from Italian centres. Gobbi et al (Gobbi, Bouquet et al. 1992) looked at 
two groups of patients with epilepsy and found a high incidence of CD in 
patients with unexplained cerebral calcification and epilepsy (24/31) and a 
high incidence of cerebral calcification in patients with CD and epilepsy (5/12). 
Low folate levels were also found which might be attributable either to 
malabsorption or chronic anticonvulsant therapy. Interestingly, cerebral 
calcifications have previously been reported in other folate deficiency states 
(Kay, Knapton et al. 1972; Flament-Durand, Ketelbant-Balasse et al. 1975).  
 
This association of intracerebral calcification with epilepsy and CD has not 
been demonstrated in an Irish study (Cronin, Jackson et al. 1998). Although 
CD was found to occur with increased frequency in patients with epilepsy 
(1/44), no patient had cerebral calcification on CT scanning suggesting that 
cerebral calcification is not a feature of epileptic patients screened at that 
hospital. This suggests that this may be an ethnic or geographic finding, 
perhaps confined to Italian populations (Figure 2.1). Many of these studies are 
case reports or small case series, and in addition are flawed by lack of 
blinding. 
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Figure 2.1 Computed tomography of the brain showing bilateral occipital 
calcifications in a patient with coeliac disease and epilepsy [photo courtesy of 
Dr Gordon Plant, The National Hospital for Neurology and Neurosurgery, 
Queen Square] 
2.3.2 Cerebellar ataxia 
Spinocerebellar and cerebellar disorders have been described by a number of 
researchers. There have been frequent reports of ataxia in classic CD where 
gastro-intestinal symptoms were concomitant or preceded the neurological 
complications (Ghezzi, Filippi et al. 1997). There are also numerous case 
reports of a cerebellar syndrome where CD was a subsequent diagnosis 
(Finelli, McEntee et al. 1980; Ward, Murphy et al. 1985; Beversdorf, Moses et 
al. 1996). Myoclonic ataxia (Ramsay-Hunt Syndrome) may be associated with 
CD (Lu, Thompson et al. 1986; Bhatia, Brown et al. 1995; Chinnery, Reading 
et al. 1997; Smith, Saldanha et al. 1997). AGA positivity has been 
demonstrated in the cerebrospinal fluid (CSF) as well as the serum of a single 
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patient with myoclonic ataxia possibly representing leakage through a 
damaged blood brain barrier (Chinnery, Reading et al. 1997).  
 
The nature of the association between idiopathic cerebellar ataxia and occult 
gluten sensitivity is controversial. An increased frequency of AGA positivity 
has been reported in patients with idiopathic ataxia (Hadjivassiliou, Grunewald 
et al. 1998; Pellecchia, Scala et al. 1999; Hadjivassiliou, Grunewald et al. 
2003) compared to control groups of ataxia of known aetiology. However, 
other researchers have not replicated these findings. 32 adult patients with 
idiopathic cerebellar ataxia were screened using AGA (IgA/IgG), ARA, EMA 
and TTG (Combarros, Infante et al. 2000). None of these patients were 
positive for any of these antibodies suggesting no association between these 
two conditions. Interestingly, Bushara and co-workers (Bushara, Goebel et al. 
2001) found a high prevalence of AGA in patients with sporadic ataxias (7/26) 
as well as hereditary ataxias (9/24) highlighting the poor specificity of AGA as 
a screening tool for gluten sensitivity. This has been confirmed by further 
VWXGLHV LQ RWKHU QHXURORJLFDO GLVRUGHUV VXFK DV +XQWLQJWRQ¶V GLVHDVH
(Bushara, Nance et al. 2004) and multiple sclerosis (Pengiran Tengah, Lock 
et al. 2004) (the latter is discussed in more detail in Chapters 7 and 8). 
These studies are relatively small and are flawed by lack of blinding and a 
reliance on AGA testing. The key published studies are summarised in  
  Type of 
study 
Number of 
patients 
Key findings 
Hadjivassiliou, 
Grunewald et 
al 
1998 Cohort 
study 
28 ataxia 
patients  
screened 
positive for 
AGA 
19 patients with 
peripheral 
neuropathy on nerve 
conduction studies 
Pellecchia, 1999 Case 24 idiopathic 3/24 idiopathic 
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Scala et al control 
study 
ataxia 
23 
symptomatic 
ataxia 
ataxia found positive 
only in the idiopathic 
group 
Combarros, 
Infante et al  
2000 Cohort 
study 
32 idiopathic 
ataxia 
No antibody 
association 
Bushara, 
Goebel et al 
2001 Case 
control 
study 
26 sporadic 
ataxia 
24 hereditary 
ataxia 
High prevalence of 
AGA in both 
hereditary and 
sporadic ataxia 
Hadjivassiliou, 
Grunewald et 
al 
2003 Case 
control 
study 
284 ataxia:- 
59 familial 
132 sporadic 
ataxia 
33 Multiple 
systems 
atrophy 
Higher prevalence of 
AGA in sporadic 
group (statistically 
significant) 
 
Table 2.1Table summarizing key findings in published studies of cerebellar 
ataxia and gluten sensitivity 
 
2.3.3 Peripheral Neuropathy 
Peripheral neuropathy in patients with established CD has been observed by 
a number of researchers (Binder, Solitare et al. 1967; Kaplan, Pack et al. 
1988; Simonati, Battistella et al. 1998) (Chin, Sander et al. 2003). The 
neuropathy may be of axonal or demyelinating type. An association with 
antiganglioside antibody has been described (Alaedini, Green et al. 2002).  
 
In two studies, the neuropathy appeared to occur because of non-compliance 
with a GFD and improved on reintroduction of a GFD (Kaplan, Pack et al. 
1988; Polizzi, Finocchiaro et al. 2000). However there is little evidence of a 
response to a GFD in other studies. These are all case reports and provide no 
strong evidence for an association. 
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2.3.4 Other Neuropsychiatric Associations 
Numerous other neurological and psychiatric disorders have been described 
in association with CD and these include myelopathy, dementia (Collin, Pirttila 
et al. 1991), brainstem encephalitis (Brucke, Kollegger et al. 1988) chorea 
(Pereira, Edwards et al. 2004) and chronic progressive leukoencephalopathy 
(Beyenburg, Scheid et al. 1998). Depression is felt to be a significant 
complication of CD (Goldberg 1970), and appears to be more severe in 
unrecognised CD (and thus untreated) or in poorly compliant patients (Hallert, 
Astrom et al. 1982). It has also been suggested that schizophrenia is 
associated with CD (Dohan 1966). However, this remains contentious, as 
other studies have not found an association (Peleg, Ben-Zion et al. 2004). 
Most of these studies are either case reports or small case series and hence 
any association is difficult to prove. 
 
2.4 Aetiology 
The aetiology of neurological diseases associated with CD remains in doubt. 
Numerous theories have been put forward including immunological, hereditary 
and nutritional. Unfortunately, the heterogeneity of associated illnesses makes 
elucidating a unifying causative effect due to CD extremely difficult. 
2.4.1 Role of Nutritional Deficits in the Neurological Complications of 
Coeliac Disease 
Nutritional deficiencies may play a role in development of neurological deficits 
in untreated CD, because of overt or occult malabsorption. Some of these are 
briefly discussed below. However, it is now acknowledged that these 
deficiencies are not sufficient factors as vitamin replacement is rarely helpful 
(Ward, Murphy et al. 1985; Lu, Thompson et al. 1986; Muller, Donnelly et al. 
1996; Simonati, Battistella et al. 1998) and hypovitaminosis is not always 
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detectable (Kaplan, Pack et al. 1988; Bhatia, Brown et al. 1995). Moreover, 
very often no neurological abnormality is detectable even in the presence of 
profound vitamin deficiency (Morris, Ajdukiewicz et al. 1970). 
 
2.4.1.1 Calcium  
Hypocalcaemia may present with neuropsychiatric complications including 
irritability, delirium, psychosis, depression, paraesthesiae around the mouth 
and distal extremities and tetany. Osteomalacic myopathy may occur with mild 
hypocalcaemia, affecting proximal muscles and associated with bony pain and 
tenderness and a raised alkaline phosphatase. Both tetany [(Rubinstein, Liron 
et al. 1982) and myopathy (Hardoff, Sharf et al. 1980) have been reported in 
CD patients. 
2.4.1.2 Folic Acid 
Folic acid deficiency has been particularly implicated in patients with CD and 
epilepsy. Ventura et al (Ventura, Bouquet et al. 1991) described two cases of 
focal occipital epilepsy with cerebral calcifications and CD. They had 
previously been poorly responsive to antiepileptics. However, a GFD and 
folate supplementation resulted in complete EEG normalisation in 1 patient 
and marked improvement in the other. Gobbi and co-workers (Gobbi, Bouquet 
et al. 1992) found low folate levels in 17 out of 19 patients with cerebral 
calcifications, epilepsy and CD, which they attributed to either malabsorption 
or anticonvulsant therapy. They suggested that low folate levels might be 
pathological as cerebral calcifications have previously been reported in other 
folate deficiency states such as in the use of antifolate treatments and 
radiotherapy in leukaemic children (Kay, Knapton et al. 1972; Flament-
Durand, Ketelbant-Balasse et al. 1975). This association was further 
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highlighted by Bye and co-workers (Bye, Andermann et al. 1993) who 
described a syndrome of bilateral occipital calcification, epilepsy and folic acid 
deficiency related to CD. In the two patients with myoclonic ataxia described 
by Lu (Lu, Thompson et al. 1986), there was subtotal villous atrophy on jejunal 
biopsy, as well as reduced folate and vitamin E levels. A GFD and vitamin 
supplementation did not improve the neurological disorder.  
2.4.1.3 Pyridoxine (Vitamin B6) 
Pyridoxine deficiency has been demonstrated in patients with CD. The 
absorption mechanism is complex. With damage to the upper duodenal 
mucosa, it appears that pyridoxine can be absorbed in the more distal 
intestine. However, this capacity appears to be rather limited (Reinken and 
Zieglauer 1978). A study by Morris et al (Morris, Ajdukiewicz et al. 1970) 
looked at the possible relationship between pyridoxine levels and neurological 
disorder in a group of 30 patients with adult CD. Although pyridoxine levels 
were lower in patients who were non-compliant with a GFD, there was no 
apparent relationship between pyridoxine levels and neurological deficit. 
Hallert and co-workers (Hallert, Astrom et al. 1983) looked at the treatment of 
depression in patients with CD and found an improvement in depressive 
symptoms after 3 years of GFD coupled with pyridoxine therapy. 
2.4.1.4 Vitamin B12 
In a study of 35 newly diagnosed CD patients, vitamin B12 deficiency was 
found in 15 (45%), 3 of who had previously developed cold peripheries and 
paraesthesiae (Dahele and Ghosh 2001). 
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2.4.1.5 Vitamin E 
Vitamin E is important for maintaining normal neurological function. 
Furthermore, in other conditions such as abetalipoproteinaemia, where 
hypovitaminosis E is secondary, vitamin E replacement may lead to 
improvement (Muller, Lloyd et al. 1983). Vitamin E deficiency has been 
demonstrated in patients with CD and this is reversible on a GFD (Muller, 
Harries et al. 1974). There are reports of CD, vitamin E deficiency and 
cerebellar ataxia with improvement following vitamin E replacement therapy 
(Mauro, Orsi et al. 1991; Battisti, Dotti et al. 1996; Beversdorf, Moses et al. 
1996). 
2.4.1.6 Biopterin 
Biopterin compounds, namely biopterin, 7,8-dihydrobiopterin, and 5,6,7,8-
tetrahydrobiopterin have an important role in the metabolism of various 
neurotransmitters. Low levels have been demonstrated in patients with CD, 
and it has been suggested that their deficiency may play a role in the 
development of neurological syndromes (Cooke 1978). Leeming and Blair 
studied mean serum biopterin levels and found these to be significantly lower 
not only in CD but also in senile dementia, lead poisoning, malignant carcinoid 
(Leeming and Blair 1980). 
2.4.1.7 Carnitine 
Carnitine is required for muscle energy production and is absorbed via a 
transport mechanism in the small bowel. A small study by Lerner et al (Lerner, 
Gruener et al. 1993) compared carnitine levels in patients with CD, 
gastrointestinal disease with a normal small bowel biopsy and normal 
subjects. Carnitine levels were significantly lower in patients with CD.  
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2.4.2 Altered Autoimmunity and Inflammatory Disorders 
Ghezzi and co-workers (Ghezzi, Filippi et al. 1997) described a man with 
known CD whose small bowel biopsy revealed ulceration and an inflammatory 
infiltrate. However, two years after diagnosis, despite a GFD, his 
gastrointestinal symptoms deteriorated and he was given steroids. His 
gastrointestinal symptoms improved but he subsequently developed a 
relapsing-remitting brainstem and cerebellar syndrome. Each relapse was 
treated with steroids and this appeared to improve his symptoms. Serial MRI 
scanning during the course of his illness showed multiple enhancing lesions. 
At the start of his illness, corticosteroid administration improved the 
appearance of the lesions on MRI. CSF examination was initially normal but 
with subsequent relapses, the presence of oligoclonal IgG bands and an 
increased CSF/serum albumin ratio was demonstrated, indicating damage to 
the blood-brain barrier. However, it could be argued that this patient had 
concurrent CD and multiple sclerosis.  
An immune mediated mechanism was also suggested in a patient with chronic 
progressive leukoencephalopathy and CD because of a CSF lymphocytosis 
and elevated serum immunoglobulin levels (Beyenburg, Scheid et al. 1998). A 
patient with treatment-resistant seizures and CD was described by Rush et al 
(Rush, Inman et al. 1986). He was found to have an isolated CNS vasculitis 
on brain biopsy. There was clinical and radiographic improvement following 
treatment with prednisolone and cyclophosphamide. 
2.4.3 Gluten neurotoxicity 
It has been suggested that gluten is neurotoxic. Dohan (Dohan 1966) 
proposed that cereals might be a cause of schizophrenia. Hadjivassiliou et al 
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((Hadjivassiliou, Gibson et al. 1996; Hadjivassiliou, Chattopadhyay et al. 1997; 
Hadjivassiliou, Grunewald et al. 1998; Hadjivassiliou, Grunewald et al. 2001; 
Hadjivassiliou, Grunewald et al. 2003) and Pellechia et al (Pellecchia, Scala et 
al. 1999) have both claimed that AGA positivity leads to immune mediated 
neurological damage. However the presence of AGA positivity in other 
conditions such as genetic ataxias (Bushara, Goebel et al. 2001), 
+XQWLQJWRQ¶V GLVHDVH (Bushara, Nance et al. 2004) and multiple sclerosis 
(Pengiran Tengah, Lock et al. 2004) suggest that AGA positivity may be an 
epiphenomenon.  
 
Cross-reaction of gluten-related antibodies with nervous system structures 
has been postulated. Antibodies cross-reacting with Purkinje cells have been 
observed (Hadjivassiliou, Boscolo et al. 2002). Another study showed 
reactivity of IgA antibodies (AGA and EMA) with human brain vessel 
structures from sera of patients with untreated CD but not from sera of CD 
patients on GFD or non-coeliac controls (Pratesi, Gandolfi et al. 1998). These 
findings were based on immunohistochemistry and non-specific binding may 
be an alternative explanation. 
 
2.5 Pathological Findings 
There is limited available histological data on patients with CD and 
neurological complications. There does not appear to be a set of distinctive or 
unifying histopathological features. Some patients have atrophy, gliosis or 
inflammatory infiltrates in a variety of combinations (Wills 2000). In the earliest 
post-mortem data of 9 coeliac patients with neurological disorder the changes 
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were mainly confined to the spinal cord and consisted spongiform changes in 
the lateral and posterior columns (Cooke and Smith 1966). 
 
Bye and co-workers (Bye, Andermann et al. 1993) reported the pathological 
findings of a patient with bilateral occipital calcifications who had a right 
occipital resection because of intractable epilepsy. The patient was 
subsequently shown to have folic acid deficiency associated with CD. The 
excised brain tissue showed patchy pial angiomatosis resembling but not 
identical to that found in Sturge-Weber syndrome. In addition, there were 
clusters of calcification, atrophic superficial and intermediate white matter, 
abundant macrophage deposition and moderate gliosis.  
 
Beyenburg et al (Beyenburg, Scheid et al. 1998) described a patient with 
chronic progressive leukoencephalopathy. Limited data available from a brain 
biopsy showed a severe reduction in myelinated nerve fibres with no evidence 
of axonal loss, a significant number of macrophages and gliosis with reactive 
astrocytes.  
 
Hadjivassiliou and co-workers (Hadjivassiliou, Grunewald et al. 1998) reported 
post mortem examination on two patients. In the first patient, there was patchy 
loss of Purkinje cells throughout the cerebellar cortex, astrocytic gliosis, 
neuropil vacuolation and a diffuse infiltrate with T cells in the cerebellar white 
matter. Perivascular cuffing with inflammatory cells, mainly T-cells but also B-
cells and macrophages, was present within the cerebellar white matter and 
posterior columns. The second patient had a normal cerebellum but 
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substantLDO SRVWHULRU FROXPQ GHJHQHUDWLRQ ZLWK D ³VSDUVH LQIODPPDWRU\
LQILOWUDWH´SUHVHQWLQWKHSHULSKHUDOQHUYRXVV\VWHP 
 
Tijssen et al (Tijssen, Thom et al. 2000) presented their pathologic findings in 
three patients with cortical myoclonus. Two of these patients had proven CD 
and the other may have had CD as suggested by low B12 levels antemortem. 
There was cerebellar atrophy and degeneration, and strikingly, Purkinje cell 
loss and Bergmann gliosis, more marked in the superficial regions. The 
primary sensory, motor, and premotor cerebral cortices, were normal except 
for unilateral gliosis of the motor cortex in one case. 
 
2.6 Treatment Potential 
2.6.1 Gluten free diet 
The established importance of treatment with a gluten-free diet in CD is that 
patients benefit from normal small bowel absorption. In addition, DH patients 
experience a resolution of the rash although for reasons that are not entirely 
clear, the response is much slower. A GFD also reduces the risk of 
development of lymphoma in coeliac patients (Holmes, Prior et al. 1989). 
Disappointingly, the potential value of a GFD in treatment or prevention 
remains unproven in the various neurological deficits already described. The 
effects of a GFD on these patients ranged from reversal of the deficit, 
stabilisation of the illness to making little or no difference. It might be that 
there is a therapeutic window of opportunity in which commencement of a 
GFD is helpful (Gobbi, Bouquet et al. 1992). 
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Hadjivassiliou and co-workers (Hadjivassiliou, Grunewald et al. 1998) made 
the intriguing observation that initiation of a GFD did lead to symptom 
resolution in some of their gluten ataxia cases. They subsequently reported on 
43 patients with idiopathic ataxia of whom 26 adhered to a GFD and showed 
marked improvement in ataxia after a one-year interval (Hadjivassiliou, 
Davies-Jones et al. 2003). This study was based on one investigator, 
XQEOLQGHG WR WKH SDWLHQWV¶ GLHWary compliance, who undertook clinical 
assessment of these patients. Further randomised controlled trials are 
required to confirm these findings.  
 
In patients with established epilepsy (Ventura, Bouquet et al. 1991; Bardella, 
Molteni et al. 1994; Lea, Harbord et al. 1995), there is limited evidence that a 
GFD prevents or stabilises seizures. Gobbi and co-workers (Gobbi, Bouquet 
et al. 1992) suggested that a GFD seems to control seizures if started near 
the onset of epilepsy and early in childhood.  
 
Although isolated peripheral neuropathy is uncommon in CD, there is some 
suggestion that treatment with a GFD may reverse the neuropathy (Kaplan, 
Pack et al. 1988). A 12-year old girl was reported with 2 episodes of 
demyelinating neuropathy with accidental introduction of dietary gluten. These 
reversed completely following re-introduction of GFD (Polizzi, Finocchiaro et 
al. 2000).  
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De Santis et al (De Santis, Addolorato et al. 1997) described a patient with 
previously diagnosed schizophrenia who following investigation for weight loss 
and diarrhoea was found to have CD (positive EMA and jejunal biopsy). A 
SPECT scan showed hypoperfusion of the left frontal area. Initiation of a GFD 
resulted in the disappearance of psychiatric symptoms as well as 
improvement in the scan appearances. 
 
Numerous studies have shown no significant improvement on a GFD (Lu, 
Thompson et al. 1986; Ghezzi, Filippi et al. 1997). Moreover, many patients 
have appeared to develop neurological complications despite adhering to a 
GFD (Cooke and Smith 1966; Beyenburg, Scheid et al. 1998). Of the 10 
cases of CD detected by Luostarinen (Luostarinen, Pirttila et al. 1999), all but 
one were started on a GFD. In six of the ten patients, there was no change in 
their neurological symptoms. One patient with neuropathy who later died of 
lymphoma actually progressed neurologically. His neuropathy was felt to be a 
paraneoplastic manifestation of the lymphoma. Two patients experienced 
some relief of their neurological symptoms (myopathy and neuropathy 
respectively) whilst a patient with epilepsy was apparently cured. 
 
2.6.2 Vitamin replacement 
Vitamin deficiency is discussed above. Vitamin replacement may play a role in 
a select group of patients. 
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2.6.3 Immunosuppressive treatment 
There have been a few reports of immunosuppressive treatment in patients 
with CD and neurological syndromes. This has been helpful in a case of 
vasculitis (Rush, Inman et al. 1986) and a case of relapsing-remitting 
brainstem-cerebellar syndrome (Ghezzi, Filippi et al. 1997). Intravenous 
steroids and immunoglobulins were not helpful in a case of progressive 
leukoencephalopathy (Beyenburg, Scheid et al. 1998). Burk and co-workers 
described four patients with AGA positivity, cerebellar ataxia but no evidence 
of gluten sensitive enteropathy who were treated with intravenous 
immunoglobulin (Burk, Melms et al. 2001). All four patients were shown to 
improve within two to three weeks. However this was an unblinded study.  
 
2.7 Discussion 
It is possible that improved case ascertainment has resulted in an apparent 
increase in the prevalence of CD. This has highlighted the changing pattern of 
presentation of CD with atypical symptoms becoming more prominent. 
However, as CD becomes more commonly diagnosed, it is likely that some 
associated diseases may merely be a result of chance. Alternatively, similar 
HLA haplotypes may confer an increased likelihood of autoimmune disease 
as exemplified by the increased incidence of hypothyroidism and Type 1 
diabetes mellitus in CD, although this too remains uncertain. 
The apparent or possible increase in prevalence of a variety of neurological 
conditions in CD suggests that patients with neurological disease are a target 
population who might benefit from screening and treatment. A causative 
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association between gluten sensitivity and neurological disorder are appealing 
because GFD may potentially be an inexpensive, relatively straightforward 
treatment option for a number of incurable conditions. However, our 
knowledge of causality remains uncertain. At present, the available data on 
neurological associations of CD is extremely heterogeneous with no 
universally acceptable scientific explanation for a causative effect. The varied 
literature on neurological complications of CD is flawed for a number of 
reasons namely referral bias, lack of blinding, difficulty of monitoring GFD for 
long periods, high prevalence of gluten sensitivity in the general population 
and also non-standardised serological testing. Furthermore, neurological 
assessment by non-neurologist is liable to inaccuracy.  
At this stage, it is possible that the majority of neurological syndromes have a 
chance association with CD. There may be a minority with a definite 
association, such as patients with certain forms of epilepsy, but further study 
is required to confirm this and the nature of the association. There are clear 
mechanisms by which patients with true gluten sensitivity can have 
neurological illness namely malabsorption and malignancy with neurological 
sequelae. Deficit of a trace element or vitamin might play an important role 
and this has considerable therapeutic implications. Thus far, this aspect of 
treatment has not been studied systematically.   
 
Malignancy has been demonstrated as a cause for neurological disease in 
patients with coeliac-related lymphoma with central neurological spread 
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(Shams, Waldman et al. 2002). A rarer but scientifically plausible alternative is 
a paraneoplastic syndrome associated with coeliac-related malignancy.  
 
The role of altered auto-immunity, particularly in susceptible HLA sub-groups, 
also merits further investigation. Moreover, with increasing recognition that CD 
is under-diagnosed, it would be prudent to be vigilant in all clinical settings. 
7KHFRQFHSWRID ³FRHOLDF LFHEHUJ´QHHGVH[WHQGLQJZLWK WKH UHDOLVDWLRQ WKDW
the potential for further research into this fascinating area of medicine is 
almost unlimited.    
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Chapter 3 - Coeliac disease and 
coexistent neurological illness: a 
retrospective study 
  52 
  
3.1 Aim 
I aimed to carry out detailed case report analysis of patients with CD and 
coexistent neurological dysfunction from data gathered nationally using the 
British Neurological Surveillance Unit (BNSU) and from my personal case 
series of patients recruited in Derby and Nottingham. This was intended to 
gain some insight into the spectrum of neurological disorders seen with CD 
 
3.2 Introduction 
A variety of neurological disorders have been reported in association with CD 
as discussed above. Mechanisms proposed include heredity, nutritional 
deficiency and an immune role for gluten. However the nature of this 
association remains unclear and indeed controversial. There are myriad 
studies detailing the various neurological diseases that occur with CD. Many 
of these are on a case report basis. There has been no detailed United 
Kingdom±wide study of neurological illnesses occurring with CD. Holmes 
(Holmes 1997) in a survey of 388 adult patients attending a CD clinic found 
102 patients (26%) had developed 132 neurological or psychiatric 
disturbances. 
3.2.1 The British Neurological Surveillance Unit 
The BNSU was established in January 1992 and is controlled by the Council 
of the Association of British Neurologists (ABN) who are responsible for the 
election of members of the BNSU advisory committee. This scientific advisory 
committee consists of neurologists and one epidemiologist who review 
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research proposals in order to ascertain the appropriateness of the use of the 
BNSU for that condition. The main criteria are that the disease should be rare, 
predominantly seen by the specialists surveyed and of sufficient scientific or 
public health interest merit. The system aims to provide a comprehensive 
surveillance system encompassing the whole of the UK in order to identify 
cases of rare neurological diseases. As a proportion of patients with 
neurological diseases are under the care of non-neurologists, other 
professional groups besides neurologists are included in this surveillance and 
asked to participate, namely paediatric neurologists, neurophysiologists and 
neuropsychiatrists. Participants are sent reporting cards on a monthly basis 
and asked to return these if they have seen the disease under investigation. 
3.3 Methods  
All patients were recruited either via the BNSU or from my own database of 
patients reported locally. All senior members of the ABN were sent monthly 
report cards for notification of any cases of neurological disorders seen with 
CD. Reporting instructions were sent out from March 2001 to March 2003. I 
contacted each Consultant who had sent a positive return, i.e. a returned card 
reporting identification of a patient with co-existent neurological disorder and 
CD, to the BNSU to obtain details of each patient (name and address). I was 
then able to contact the patient directly in order to obtain signed consent 
allowing access to their casenotes and to send him/her a copy of the consent 
form to keep as well as a patient information leaflet. Where consent was not 
possible e.g. if the patient had died, attempts were made to obtain 
anonymised casenotes. 
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My database consisted of patients with co-existent CD and neurological 
disorder that I had identified myself or that had been identified by my 
colleagues within the Departments of Neurology at the Queens Medical 
Centre, Nottingham and the Derbyshire Royal Infirmary, Derby. 
 
Data collected included neurological diagnosis, age and sex of the patient and 
length of time from diagnosis of CD to diagnosis of neurological disorder. 
3.3.1 Ethical considerations 
I had Multi-Centre Regional Ethics Committee (MREC) approval from Ethics 
Committees of both the 4XHHQ¶V 0HGLFDO &HQWUH 1RWWLQJKDP DQG 6RXWKHUQ
Derbyshire Health Authority, Derby.  
 
3.4 Results 
In 24 months of reporting, 23 positive returns were received from the BNSU. 
This is comparable in rarity to other case series of rare neurological conditions 
reported via the BNSU e.g. paraneoplastic neurological syndromes (7 cases 
SHU \HDU DQG 'XDQH¶V V\QGURPH  FDVHV SHU \HDU 13 patients were 
included in my coeliac neurology database from my personal case series and 
reporting from local colleagues in Derby and Nottingham between April 2000 
and October 2002 (31 months). Three patients were unable to give signed 
consent although I had anonymised notes of 1 patient. 1 patient declined to 
participate. 1 patient did not return consent. I did not receive patient contact 
details/casenotes of 15 patients.  
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I was therefore able to review 18 sets of casenotes. Neurological disorders 
included epilepsy [4 (22%); 1 with learning difficulty], stroke [3, (17%)], extra-
pyramidal disorder [2 (11%)], migraine [2 (11%); 1 with subtle dysphasia and 
cognitive impairment], myelopathy [1 (6%)], axonal neuropathy [1 (6%)], 
paraneoplastic ataxia [1 (6%)], Lambert Eaton myasthenic syndrome [1 (6%)], 
akathisia [1 (6%)], facial numbness [1 (6%)] and memory disturbance [1 (6%)]. 
All 4 of the patients with epilepsy had had computed tomography of the brain. 
1RQHKDGRFFLSLWDOFDOFLILFDWLRQV1RFDVHVRIµJOXWHQDWD[LD¶ZHUHUHSRUWHG 
 
The male:female ratio was 1:1 with mean age 53 yrs 10 months (Range 35 
yrs 7 months to 69 yrs 7 months). Details of date of diagnosis of CD, and 
hence length of treatment with GFD, were not available in the majority of the 
patients although CD predated the neurological diagnosis in all patients 
reviewed. However in the 5 patients in whom it was available, CD predated 
presentation to a neurologist from 9 months to 30 yrs. These findings are 
summarised in Table 3.1 below. 
 
 
Patient Age Sex Neurological 
disorder 
Time from CD 
diagnosis to 
neurological 
diagnosis 
1 38y 7m M Epilepsy + mild 
learning difficulty 
30 years 
2 48y 2m F Myelopathy N/A 
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3 61y 10m M Axonal neuropathy 24years 
4 48y 3m F Migraine 9 months 
5 47y 10m F Stroke N/A 
6 48y 2m M Stroke 10 years 
7 48y 7m F Facial numbness N/A 
8 69y 1 m F 3DUNLQVRQ¶V disease N/A 
9 64y 4m M Lambert-Eaton 
myasthenic syndrome 
N/A 
10 56y 11m M Epilepsy N/A 
11 39y 6m F Migraine N/A 
12 65y 2m M Venous sinus 
thrombosis 
N/A 
13 69y 7m F Akathisia 20 years 
14 45y 3m M Memory difficulty N/A 
15 61y 9m F Extrapyramidal 
syndrome 
N/A 
16 35y 7m F Epilepsy N/A 
17 65y 1 m M Paraneoplastic ataxic 
syndrome 
N/A 
18 55y 11m M Epilepsy N/A 
 
Table 3.1 Table summarizing age, sex, neurological deficit and time from 
coeliac disease diagnosis to neurological diagnosis in a series of patients with 
coeliac disease and neurological illness 
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3.5 Discussion 
The BNSU is a valuable aid in the study of rare disorders but in less severe 
conditions, such a method of ascertainment inevitably underestimates 
prevalence and is prone to selection bias towards patients with associated 
morbidity. This is a major limitation of this study. Furthermore the system 
depends very much on the enthusiasm of reporting clinicians. My own local 
case series on the other hand is likely to be prone to ascertainment bias. 
However the intention of this study was to gain some insight into the scope of 
neurological disorders seen with CD rather than true prevalence.  
 
CD and coexistent neurological dysfunction is only rarely reported in a 
neurological setting. This is the first UK-based surveillance study of CD and 
coexistent neurological dysfunction. BNSU reporting combined with local 
experience in Nottingham and Derby suggests that the association of CD and 
neurological disorders is rare and that patients reported in this surveillance 
study formed a heterogeneous group with the commonest neurological 
association being epilepsy and stroke. This may suggest an increased 
incidence of epilepsy and stroke with CD but is more likely to reflect the fact 
that these are conditions commonly seen in a neurological setting.  
 
Diagnosis of CD and subsequent GFD predated the neurological diagnosis in 
all cases reviewed suggesting that the neurological disorders were unrelated 
to gluten exposure. However I did not have sufficient data regarding time from 
diagnosis of CD to onset of neurological disease, or indeed level of 
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compliance with a GFD, which may have been a useful surrogate marker of 
gluten exposure.  
 
Adherence to GMC guidelines for disclosure of information has made 
retrospective studies like this increasingly difficult. A major factor in data 
collection was the recent more stringent guideline issued by the General 
0HGLFDO&RXQFLO*0&ZKLFKVWDWHVWKDWWKHUHVHDUFKHUVKRXOG³VHHNFRQVHQW
to the disclRVXUH RI DQ\ LQIRUPDWLRQ ZKHUHYHU «SUDFWLFDEOH´ :KHUH
obtaining consent is not practicable the guidelines suggest that data can be 
anonymised, although even in a case such as this ideally patients should be 
given the opportunity to object.  
 
In order to proceed with building up this case series, where possible I 
requested signed consent from each patient allowing us to examine his/her 
case notes. The cases where seeking consent was deemed not practicable 
were usually communicated to me as such by the reporting consultant on the 
grounds of recent death of the patient, severe illness or lacking capacity to 
give consent. I did not attempt to obtain consent from relatives for two main 
reasons. Firstly, the GMC guidance states that no one can give or withhold 
consent on behalf of an adult with mental incapacity. Secondly, I did not wish 
to cause further distress to the recently bereaved families. In these cases I 
attempted to obtain anonymised data although this proved to be impractical 
and largely unsuccessful. 
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To conclude, I did not feel that this small case series supports a hypothesis of 
a neurological syndrome as a result of CD. However, further study was 
required to confirm or refute an association between CD and neurological 
illness. 
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Chapter 4 - Prevalence of neurological 
disorders in patients with gluten 
sensitivity 
  61 
 
4.1 Aims 
I aimed to examine case records of a large cohort of CD patients in order to 
establish prevalence of neurological disorders. I also aimed to carry out more 
detailed investigation of a subgroup of patients from this cohort said to have 
epilepsy for more accurate prevalence of epilepsy and to discover whether a 
specific epilepsy syndrome exists in this group of patients. 
 
4.2 Introduction 
There have been various descriptions of neurological disorder complicating 
CD including peripheral neuropathy (Kaplan, Pack et al. 1988) and cerebellar 
ataxia (Hadjivassiliou, Grunewald et al. 1998). Malabsorption and gluten 
neurotoxicity are proposed explanations. Studies looking at prevalence of 
neurological disorders are flawed by differences in study criteria and variable 
GHILQLWLRQV RI µQHXURORJLFDO GLVRUGHU¶ 0RVW SUHYDOHQFH DQDO\VHV KDYH EHHQ
performed in selected patient groups in tertiary referral centres. Assessment 
of neurological disorder by a non-neurologist may be liable to inaccuracy. 
Interpretation of studies is complicated because CD is common and often 
occult as most patients with gluten sensitive enteropathy are asymptomatic. 
One study that included complications secondary to malabsorption found that 
neurological symptoms occur in 36% of CD patients (Kinney, Burger et al. 
1982). Finelli et al (Finelli, McEntee et al. 1980) estimated that 10% of patients 
with coeliac disease develop neurological complications.  
 
  62 
4.2.1 Epilepsy and gluten sensitivity 
The available published literature suggests an association between CD and 
certain forms of epilepsy, An increased prevalence of epilepsy in patients with 
established CD has been reported (Chapman, Laidlow et al. 1978). Studies 
from Italian centres have suggested an association between CD and epilepsy 
with cerebral calcifications (Gobbi, Bouquet et al. 1992) although this has not 
been found in Irish and Finnish populations (Cronin, Jackson et al. 1998; 
Luostarinen, Dastidar et al. 2001). Low folate levels, attributable to chronic 
anticonvulsant therapy or malabsorption, have been implicated. Cerebral 
calcifications are found in other folate deficient states (e.g. following treatment 
of childhood leukaemia with Methotrexate). 
 
The majority of studies investigating the association of CD with epilepsy have 
found an increased prevalence of CD in cohorts of patients with epilepsy 
(Cronin, Jackson et al. 1998; Pratesi, Gandolfi et al. 2003). However, in 
children with localisation-related epilepsy, only those with occipital paroxysms 
seem to have an increased prevalence of occult coeliac disease (Labate, 
Gambardella et al. 2001). The prevalence of epilepsy in CD patients has been 
reported twice (Chapman, Laidlow et al. 1978; Hanly, Stassen et al. 1982).  
 
4.3 Methods 
In 1978 a register of patients with CD in the catchment area of the Derby 
Hospitals (Derbyshire Royal Infirmary and Derby City General Hospital) was 
established. All patients diagnosed before this time and subsequently were 
added to the register. Strenuous efforts were made to identify all patients with 
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CD in the area and sources included the hospital diagnostic index, pathology 
records, the Dermatitis Herpetiformis Clinic, the Immunological Laboratory, 
the Dietetic Department and membership lists of the Coeliac Society. Since 
1978, regular fortnightly meetings with the histopathologists have reviewed all 
small bowel biopsies. It is thus highly likely that the vast majority of patients in 
the catchment area of the Derby Hospitals with CD have been identified.  
 
A dedicated clinic for CD was set up to act as a focus for patient care and 
research and has been run personally by Dr GKT Holmes (GKTH) ever since. 
By the end of 2002, 801 unselected adult patients (over the age of 15 years) 
with CD had attended the clinic on at least one if not several occasions. 
 
The diagnosis of CD was confirmed by small bowel biopsy in each patient. Case 
notes were available for review in all of the patients. Of these 91 cases (32 
male; mean age at diagnosis 3 years 4 months, range 4 months to 14 years 6 
months) were diagnosed in childhood but were referred by paediatricians to the 
clinic at the age of 15 years for follow up. Of the 710 remaining cases (226 male; 
mean age at diagnosis 47 years, range 15 to 88 years) diagnosed during adult 
life, 36 were diagnosed prior to 1978 and all but seven of these who had died 
were seen in the clinic. Although full notes were available on these seven cases 
and none appeared to have had any neurological disorders, they were not seen 
in the clinic and have not been considered in the analysis.  A database of all 
other medical conditions in these patients was compiled and maintained by 
GKTH by regular case note review. It was therefore possible to identify the types 
and frequency of neurological conditions in these patients. 
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21 patients (2.6%) were identified with a lifetime history of seizures. Their 
case notes were then reviewed to establish the seizure type, frequency and 
the results of investigations.   
 
4.4 Results 
4.4.1 Prevalence of neurological disorders in patients with proven 
coeliac disease 
Of 801 patients within the CD database, 54 neurological disorders were found 
in 177 patients (22%). The commonest diagnoses are listed in Table 4.1 
below. Some patients had more than 1 disorder. The commonest diagnoses 
found were stroke, migraine, epilepsy and carpal tunnel syndrome which 
made up 13.1%, 12.6%, 12.0% and 9.1% of the neurological conditions 
respectively and 2.9%, 2.7%, 2.6% and 2.0% of the total number of patients 
respectively. No patients with idiopathic cerebellar ataxia were identified.  
 
Neurological disorder 
Frequency 
 
% of total 
neurological 
conditions 
(N=175) 
% of total 
patients 
(N=801) 
Stroke 23 13.1 2.9 
Migraine 22 12.6 2.7 
Epilepsy 21 12.0 2.6 
Carpal tunnel syndrome 16 9.1 2.0 
Herpes zoster 6 3.4 0.7 
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Tension Headache 6 3.4 0.7 
Sciatica 5 2.9 0.6 
Learning disabled 4 2.3 0.5 
Parkinson's 4 2.3 0.5 
Meningitis 4 2.3 0.5 
Deaf 4 2.3 0.5 
Multiple sclerosis 4 2.3 0.5 
Dementia 3 1.7 0.4 
Peripheral neuropathy 3 1.7 0.4 
Squint 3 1.7 0.4 
Retinal vein (or branch) occlusion 3 1.7 0.4 
Benign essential tremor 2 1.1 0.2 
Down's syndrome 2 1.1 0.2 
%HOO¶VSDOV\ 2 1.1 0.2 
Cubital tunnel decompression 2 1.1 0.2 
Tinnitus 2 1.1 0.2 
Meniere's 2 1.1 0.2 
Others 32 18.3 4.0 
 
Table 4.1 Prevalence of neurological disorders in 801 patients with coeliac 
disease 
 
4.4.2 Prevalence of epilepsy in patients with coeliac disease 
21 patients had a lifetime history of seizures and nine patients had active 
epilepsy (six focal epilepsy cases, three generalised) as defined by any 
seizure in the preceding five years. One patient had childhood onset febrile 
convulsions. The seizure sub-type in the remaining 20 patients was 
generalised in 12 cases (childhood absences-2, primary generalised in 3, 
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cryptogenic in 7), focal in seven cases (1 multiple strokes, 1 cortical 
heterotopia) and secondary to hypoglycaemic attacks complicating diabetes 
mellitus in one case. The development of CD preceded the onset of seizures 
in seven out of 21 cases. The onset of seizures occurred at a mean age of 20 
years in this cohort of patients (range birth to 87 years), whereas the onset of 
CD occurred at a mean of 38 years (range 1 to 85 years). All the patients with 
active epilepsy were on anticonvulsant medication. In those cases where CD 
preceded the onset of epilepsy the patients had been on a gluten free diet for 
between 1 to 15 years. The clinical characteristics of the patients are shown in 
table 4.2 (active epilepsy in bold). 
 
 SEX CD ONSET  
YEARS 
EPILEPSY ONSET 
YEARS 
SEIZURE TYPE 
1 M 16 2 FOCAL 
2 F 64 59 CRYPTOGENIC GENERALISED 
3 F 25 3 TYPICAL ABSENCE 
4 F 52 23 FOCAL 
5 F 1.5 2 FEBRILE CONVULSIONS 
6 F 61 9 FOCAL 
7 F 49 7 CRYPTOGENIC GENERALISED 
8 F 48 14 PRIMARY GENERALISED 
9 M 85 87 SECONDARY GENERALISED 
MULTIPLE STROKES 
10 M 1 9 CRYPTOGENIC GENERALISED 
11 F 35 45 FOCAL 
12 M 55 PERINATAL FOCAL 
13 F 53 PERINATAL CRYPTOGENIC GENERALISED 
14 M 2 16 PRIMARY GENERALISED 
15 M 53 29 CRYPTOGENIC GENERALISED 
16 F 2 1.5 CRYPTOGENIC GENERALISED 
17 F 36 14 FOCAL 
  67 
18 F 26 21 PRIMARY GENERALISED 
19 F 76 19 CRYPTOGENIC GENERALISED 
20 F 28 40 HYPOGLYCAEMIA 
21 F 43 21 FOCAL 
CD-coeliac disease, M-Male, F-Female 
Table 4.2 Prevalence of epilepsy obtained from a database of an unselected 
cohort of 801 patients with coeliac disease (Active epilepsy in bold) 
 
4.5 Discussion  
In this large database of 801 CD patients, numerous different neurological 
diagnoses have been recorded in their hospital case notes. However the 
robustness of these diagnoses were not confirmed. A prevalence of 
neurological disorder of 22% is higher than has previously been reported. This 
may approach a true prevalence because great care has been taken to 
include as much clinical detail regarding these patients into the database as 
possible. However, some neurological disorders may have been missed e.g. 
those seen at other hospitals or in primary care. Therefore no firm conclusions 
are made about the prevalence of each of these conditions from this data 
apart from epilepsy which was reviewed in more depth. 
 
Epilepsy does not appear to be significantly more common than in the general 
population in our 801 CD patients. 1.1% of CD patients had active epilepsy 
compared with a general prevalence of 0.5%-1.0% (Sander 2003). Assuming 
a mid-point prevalence of 0.73% (Wright, Pickard et al. 2000) (from a 
background population of 225000) this gives a 95% confidence interval of the 
difference between the two proportions of ±1.39 to 0.14% (p=0.12 - Miettinen 
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test). Furthermore, no consistent temporal relationship was found between the 
development of CD and epilepsy.  
 
It is unlikely that these results arise from selection bias because great efforts 
were made to identify all patients with diagnosed CD in the area. The patients 
included in this study represent a prevalence of CD in the local background 
population of approximately 1 in 625. There remain many undiagnosed 
patients in this area because screening studies give a prevalence of 1% but 
there is no reason to believe that the frequency of epilepsy is any different in 
this group.   
 
Previous studies in CD populations have provided conflicting data on the 
prevalence of epilepsy. Chapman and co-workers identified 185 CD patients 
and found that nine subjects had active seizures (5.5%), predominantly of 
complex partial epilepsy (Chapman, Laidlow et al. 1978). Hanly et al found a 
prevalence of epilepsy in 1% of 177 CD patients (Hanly, Stassen et al. 1982). 
Both of these studies used structured questionnaires sent to the patients prior 
to neurological review. It could be argued that the figures in this study are 
under-represented as I relied on information from clinical interviews rather 
than standardised questionnaires to establish a seizure history.  
 
How CD might predispose subjects to epilepsy is unclear. Some authors have 
argued that gluten is neurotoxic (Hadjivassiliou, Boscolo et al. 2002), whereas 
others have suggested that pyridoxine or folate deficiency might lower the 
seizure threshold (Lea, Harbord et al. 1995). If gluten is neurotoxic, a gluten 
  69 
free diet (GFD) could reduce the risk of epilepsy in CD. Ventura and co-
workers described two cases of refractory focal occipital epilepsy, cerebral 
calcifications and CD who showed marked improvement on a GFD and folate 
supplementation (Ventura, Bouquet et al. 1991).  
 
This study highlights a number of points with regards to the association of CD 
with neurological illness in general and epilepsy in particular. The strength of 
the study is that it comprises a large series of unselected CD cases 
comprising all CD patients diagnosed within the catchment area of the Derby 
Hospitals in Southern Derbyshire. This is not a tertiary referral centre so 
patients with CD are more likely to be representative of those in the general 
population. Any further comparison to the general population is less accurate 
as there are likely to be numerous other confounding variables e.g. access to 
diagnosis and treatment, differences in demographics and lifestyle. In addition 
there may be under-reporting of neurological conditions within the database 
as this was compiled by non-neurologists and casenotes are unlikely to hold 
all pertinent medical information. However, this may be less of a factor 
because there was active scrutiny for additional diagnoses in these patients 
during the course of their follow-up. Conversely there may be reverse 
causality as patients attending medical practitioners regularly are more likely 
to be diagnosed with illness even if disease prevalence is the same. Another 
weakness of this study is that I did not obtain figures for the prevalence of 
epilepsy in a suitable control group such as in patients with gastro-intestinal 
reflux.  
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Review of general practitioner records might provide an alternative method of 
investigating the question of association of CD and neurological dysfunction. 
To my knowledge this approach has not been utilised previously, but the 
General Practitioner Research Database (GPRD) might facilitate such studies 
in future. However, I feel that the results are likely to be more accurate than 
those that could be obtained from analysis of the GPRD, because of 
uncertainties about the accuracy and consistency of GP records documenting 
the presence of seizures. 
 
In conclusion, this study confirms that numerous neurological disorders are 
found in a coeliac population. The mechanisms underlying this association 
remain unclear. No cases of ataxia, (gluten or otherwise) were identified in 
this cohort of CD patients. The current study suggests that there is no specific 
association between CD and epilepsy. Further case-control studies are 
required to determine whether there is a consistently observed association 
between gluten sensitive diseases and other neurological illnesses. 
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Chapter 5 ± Dermatitis herpetiformis, 
coeliac disease and neurological 
dysfunction 
  72 
 
5.1 Aims 
This study aimed to thoroughly investigate cohorts of patients with CD and DH 
to determine the prevalence of neurological complications. I propose that if 
gluten is indeed neurotoxic that patients with DH having chronic gluten 
exposure should have an increased frequency of neurological disorders.  
 
5.2 Introduction 
Patients with CD are well recognised to be at risk of developing complications 
that increase mortality and morbidity. Whilst malignant complications have 
been emphasised in the past, it is only in recent years that researchers have 
turned their attention to other potential associations such as Type I diabetes 
mellitus, hypothyroidism and osteoporosis. As has been mentioned, 
prevalence data from studies looking for neurological complications of gluten 
sensitivity are flawed for a number of reasons including selection criteria and 
variable criteria for definition of neurological disorder.  
 
Neurological disorders are said to be found in 10% of patients with CD (Finelli, 
McEntee et al. 1980). However it is likely that detailed neurological 
assessment would make this figure higher. Malabsorption, whether overt or 
occult, is a cardinal feature of untreated CD and may result in nutritional 
deficiencies that potentially play a role in development of neurological deficits. 
However vitamin deficiency is not always present (Bhatia, Brown et al. 1995), 
vitamin replacement is not always helpful (Lu, Thompson et al. 1986) and 
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often no neurological complications occur even with severe vitamin deficiency. 
No other definite explanation for an association between CD and neurological 
dysfunction exists although some authors have proposed a neurotoxic role for 
gluten (Hadjivassiliou, Grunewald et al. 2003). This hypothesis is an 
unsatisfactory explanation as some patients develop a neurological disorder 
despite strict adherence to a GFD. 
 
One study found a low prevalence of neurological disorders in 305 patients 
with DH (Reunala and Collin 1997). Whilst classical CD is a gluten sensitive 
enteropathy, DH is a blistering skin disease characterised by IgA deposition in 
papillary dermis. There is robust immuno-pathological and genetic evidence 
that DH and CD are closely related conditions. DH has a similar incidence of 
the HLA haplotypes DR3/DQ2 to CD. Twin and family studies also support 
this association. GFD may be used to treat DH but patients may take up to 2 
years to respond to gluten restriction and therefore patients are routinely 
offered dapsone. In the absence of enteric symptoms, compliance to GFD 
may be poor. DH tends to present later than CD and thus exposure to gluten 
is longer. Therefore, if gluten toxicity results in neurological complications, 
these should also occur in DH patients and potentially with increased 
frequency compared to CD patients. 
 
5.3 Methods 
A group of 35 patients with DH was identified from Dermatology outpatient 
FOLQLFV DW 6W 0DU\¶V +RVSLWDO /RQGRQ DQG the 4XHHQ¶s Medical Centre, 
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Nottingham from November 1999 to April 2000. All the latter group of patients 
had presented with a rash and the diagnosis of DH had been previously 
confirmed by skin biopsy showing characteristic IgA deposits in the 
dermoepidermal junction on direct immunofluorescence. These patients were 
examined by Dr. AJ Wills, Consultant Neurologist and Dr. B. Turner, Specialist 
Registrar in Neurology.  
 
A description of the register of patients with CD in the catchment area of the 
Derby Hospitals is given in the previous chapter. From November 2000 to 
May 2002, I identified 53 patients from the CD clinic at the Derbyshire Royal 
Infirmary, Derby (set up to act as a focus for patient care and research and 
run personally by Dr GKT Holmes since inception of the Derby CD register in 
1978). Fifty two of these 53 patients had had confirmatory small bowel biopsy 
except 1 with severe latex allergy in whom serological testing was 
convincingly positive (IgA AGA and EMA). These patients were examined by 
me.  
 
Each patient was questioned about previous and current neurological and 
enteric symptoms. All patients underwent thorough neurological examination 
and casenote review. Nerve conduction studies were requested where 
appropriate. All patients gave informed written consent. 
5.3.1 Ethical considerations 
I had Multi-Centre Regional Ethics Committee (MREC) approval from Ethics 
&RPPLWWHHV RI ERWK WKH 4XHHQ¶V 0HGLFDO &HQWUH 1RWWLQJKDP DQG 6RXWKHUQ
Derbyshire Health Authority, Derby.  
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5.4 Results 
5.4.1 Neurological abnormalities in patients with dermatitis herpetiformis 
Thirty five patients with confirmed DH were identified with mean age 59 years 
(range 13-81) and mean disease duration 20 years (range 3-42). Thirty two 
patients had had intestinal biopsies of which 27 (84%) showed villous atrophy. 
Only 11 of these 27 had ever reported any gastrointestinal symptoms. 
Fourteen of the 35 patients were controlled by a GFD alone although 
compliance may have been poor in a proportion of these patients. Fifteen 
patients required dapsone as well as adhering to a partial GFD. Six patients 
chose not to take a GFD and the rash was controlled with dapsone alone. 
Neurological abnormalities that were identified in the DH cohort were chorea 
(1), essential tremor (1) and migraine (2). The patient with chorea had been 
taking long term phenytoin after a single seizure in 1985 at the age of 61. The 
clinical details are summarized in Table 5.1 below.  
 
Patient 
No 
Age Disease 
Duration 
Sex Dapsone Neurological 
abnormality 
1 81 4 M Yes None 
2 55 37 M Yes None 
3 61 3 F Yes Migraine 
4 66 7 F Yes None 
5 51 8 M Yes None 
6 13 4 F Yes None 
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7 63 26 F No None 
8 45 7 M Yes None 
9 65 30 F No None 
10 62 30 F Yes None 
11 78 27 M No None 
12 36 21 F Yes None 
13 37 5 F Yes None 
14 64 12 M No None 
15 60 17 M No None 
16 59 42 M Yes None 
17 73 4 F Yes None 
18 64 12 M No None 
19 52 14 M Yes None 
20 67 27 M Yes None 
21 69 22 F No None 
22 65 29 M No None 
23 73 10 M Yes None 
24 74 30 M Yes Essential tremor 
25 56 21 M No None 
26 48 26 M Yes None 
27 68 38 M No None 
28 59 9 F Yes None 
29 40 16 F No None 
30 66 20 F No None 
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31 75 25 F No Chorea 
32 59 12 M Yes None 
33 60 9 M Yes None 
34 56 38 F Yes Migraine 
35 55 35 F No None 
 
Table 5.1 Clinical details of a cohort of 35 patients with dermatitis 
herpetiformis including any associated neurological disorder 
 
No cases of myoclonus, ataxia, dementia or peripheral neuropathy were 
detected in this cohort. One further patient with a history of lumbar spine 
surgery had absent ankle jerks. His nerve conduction studies were normal in 
the upper limbs and showed only motor abnormalities in the lower limbs 
suggesting a lumbar radiculopathy secondary to previous surgery (lateral 
SRSOLWHDO &0$3  P9 VXUDO 6$3 ȝ9 $QRWKHU SDWLHQW KDG GHSUHVVHG
upper limb reflexes which improved with clinical reinforcement. Nerve 
conduction studies were normal and this patient was judged normal. 
5.4.2 Neurological abnormalities in patients with coeliac disease 
53 patients with confirmed CD were identified with a mean age 48 years 
(range 18-88). Twenty-two patients had newly diagnosed CD (awaiting or 
newly started on GFD) with mean age 53 (range 21-88). Thirty-one patients 
had established disease (GFD longer than 1 year) with mean age 45 (range 
18-81). Patients already on GFD had received this for a mean of 11 years 
(range 1-26). Nine neurological abnormalities that were identified in 16 of 53 
patients were epilepsy (1), restless legs syndrome (1), carpal tunnel syndrome 
(1), benign fasciculations (1), multiple sclerosis (1), S\GHQKDP¶VFKRUHD 
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cluster headache (1), diabetic neuropathy (2) and migraine (7). Idiopathic 
neurological dysfunction occurred in 13 of 53 patients overall (25%). In the 
newly diagnosed group, the prevalence of idiopathic neurological diseases 
was 6 of 22 (27%) whilst in the established group the prevalence was 7 of 31 
(23%). No cases of myoclonus or dementia were detected in this cohort. The 
clinical details are summarized in Tables 5.2(a) and 5.2(b) below.  
 
Patient Number Age Sex Neurological 
abnormality 
1 53 M Epilepsy 
2 42 F None 
3 75 M None 
4 63 M Diabetic neuropathy 
5 52 F None 
6 33 F None 
7 45 F None 
8 82 F None 
9 36 F Migraine 
10 56 M Benign fasciculations 
11 42 F Multiple sclerosis 
12 31 M Cluster headache 
13 88 F Migraine 
14 21 F None 
15 62 M None 
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16 61 M None 
17 43 F None 
18 70 F None 
19 49 M None 
20 50 F None 
21 56 F None 
22 53 M Diabetic neuropathy 
 
Table 5.2(a) Clinical details of 22 patients with newly-diagnosed coeliac 
disease including any associated neurological disorder 
 
Patient No Age Disease Duration Sex Neurological abnormality 
23 40 1 F None 
24 47 10 F None 
25 77 5 F None 
26 18 14 F None 
27 44 15 F None 
28 65 7 F None 
29 54 16 F Restless legs syndrome 
30 60 6 M None 
31 48 6 F None 
32 37 5 F None 
33 41 5 F Carpal tunnel syndrome 
34 55 17 F None 
35 53 26 F None 
36 27 5 F None 
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37 47 18 F None 
38 60 21 F Migraine 
39 28 21 F None 
40 38 10 F Migraine 
41 30 1 F None 
42 63 11 F None 
43 32 1 F None 
44 70 8 F None 
45 34 13 F None 
46 48 21 F None 
47 42 1 F None 
48 26 25 F 6\GHQKDP¶VFKRUHD 
49 26 25 F Migraine 
50 45 1 M None 
51 30 7 F Migraine 
52 39 15 F Migraine 
53 81 7 F None 
 
Table 5.2(b) Clinical details of 31 patients with established coeliac disease 
including any associated neurological disorder 
 
Two patients, both with newly-diagnosed CD, had diabetic neuropathy. One 
(patient 4) was a non-insulin dependent diabetic and asymptomatic but was 
found to have areflexia and reduced pinprick and vibration sense in a stocking 
distribution. The other (patient 22) was insulin dependent and had other 
evidence of end-organ disease namely diabetic retinopathy.  Two other 
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patients had diabetes (patient 1 diet-controlled and patient 44 with 
longstanding insulin-dependent diabetes) but neither had symptoms or signs 
of neuropathy. 
 
The patient with epilepsy was stable on phenytoin. It was therefore not felt 
that brain imaging to exclude cerebral calcifications was justifiable.  
 
2I LQWHUHVW ZDV WKH SDWLHQW ZLWK 6\GHQKDP¶V &KRUHD (patient 48). She had 
presented at the age of 15 in 1990 with short-lived ataxia and chorea following 
an acute illness with headache and vomiting. At the time she was seen by a 
Consultant Neurologist who made this diagnosis. She had been established 
and compliant with a GFD since the age of 3 years. On formal neurological 
examination there are currently no abnormalities detectable. Her twin sister 
was also included in this study (patient 49). She had not suffered with the 
same ataxic illness as her twin. 
 
The patient with benign fasciculations (patient 10) was discovered to have 
these on examination in the course of this study. He has not shown any 
neurological deterioration. His voltage-gated potassium channel antibodies 
were negative.  
 
Another patient was found to have absent ankle jerks bilaterally with reduced 
vibration sense on the left. There was a history of sciatica. His nerve 
conduction studies were normal. One further patient had absent upper limb 
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reflexes but normal nerve conduction studies and this patient was also judged 
normal. 
5.5 Discussion  
This retrospective study has shown a low prevalence of idiopathic 
neurological abnormalities in DH (4/35, 11%). Essential tremor (1/35) and 
migraine (2/35) are sufficiently common in the general population for this to 
have been a chance association. The prevalence of essential tremor may be 
as high as 50/1000 in those older than 60 (Louis, Ottman et al. 1998). Twenty 
patients in the DH cohort were over 60. The 1 year prevalence of migraine is 
25% (Launer, Terwindt et al. 1999). There have been isolated case reports of 
patients with chorea associated with chronic phenytoin administration. 
However chorea has also been reported in association with CD (Pereira, 
Edwards et al. 2004). This patient had been on a strict GFD with no evidence 
of dietary indiscretion so it is suggested that gluten toxicity did not play an 
aetiological role. 
 
The prevalence of idiopathic neurological disorder in the CD cohort is 25% 
(13/53) however, the DH group is not significantly different from the CD group 
(Fisher's exact test p=0.17). The prevalence of neurological disorder is higher 
than the DH cohort but is probably skewed by the high prevalence of 
migraine. However, as mentioned above, migraine is relatively common. 
There is a conflicting literature with regards to prevalence of migraine in CD 
with some authors supporting an association (Cicarelli, Della Rocca et al. 
2003) whilst others not (Gabrielli, Cremonini et al. 2003). Similarly, restless 
legs syndrome, carpal tunnel syndrome, multiple sclerosis and cluster 
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headache are also sufficiently frequent to be chance associations with 
estimated prevalences of 10.6% (Berger, Luedemann et al. 2004), 9.2% (de 
Krom, Knipschild et al. 1992), approximately 1 in 500 in Scotland (Rothwell 
and Charlton 1998) and 1 in 500 (Russell 2004) respectively.  
 
The underlying association between benign fasciculations and CD is not 
known and has not been previously reported. Whilst it is now recognised that 
the cramp-fasciculation syndrome has an auto-immune basis (Newsom-Davis, 
Buckley et al. 2003) this patient was asymptomatic, did not progress and his 
voltage-gated potassium channel antibody was negative and hence no auto-
immune association can be inferred.  
 
The prevalence of epilepsy is discussed in the previous chapter. General 
prevalence of epilepsy is 0.5 to1% compared to 2% (n=1) in this cohort of 53.  
 
No cases of gluten ataxia or idiopathic neuropathy were seen in either the DH 
or CD cohorts.   
 
If gluten is neurotoxic, patients with a greater gluten exposure should be at 
higher risk of neurological complications. The lack of association between DH 
and neurological sequelae is therefore an important finding as these patients 
often have no enteric symptoms, and their skin symptoms may be well-
controlled on dapsone alone. Furthermore the cohort of newly-diagnosed CD 
patients was older (mean age 53 compared to patients established on GFD 
with mean age 45) and therefore overall also had a long exposure to gluten. 
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There was no significant difference between prevalence of neurological 
disorders in the newly-diagnosed and established cohorts of CD patients.  
This study does not support a role of gluten in causing neuronal damage. 
Certainly it challenges the notion of a dose-related effect. No evidence of 
immune-mediated neurological damage other than the patient with likely post-
infectious chorea was found. The role of disordered biopterin synthesis or 
trace element deficiencies such as thiamine, niacin and pyridoxine, has not 
been analysed in this study. 
 
The numbers of patients in this study was relatively small. However each case 
was subjected to detailed history-taking and examination by a neurologist and 
hence there is a degree of accuracy pertaining to each sXEMHFW¶VQHXURORJLFDO
status. The higher prevalence of neurological disorders seen in these patients 
compared to those described in the previous chapter is likely to be accounted 
for by this being neurologist-led as opposed to the database/notes review 
described in the previous chapter which may be flawed by less sensitive 
identification of neurological disorder by non-neurologists.  
 
An important deficiency is the lack of a gastroenterological control population 
such as patients with irritable bowel syndrome (IBS). 
 
To conclude, it was felt that the neurological abnormalities found in these 
patients are likely to be either chance or spurious associations. No cases of 
gluten ataxia were discovered nor was there evidence of immune-mediated 
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neurological damage. The hypothesis of a relationship between DH and CD 
with neurological abnormality remains unproven.  
 
Further prospective studies should be carried out in large populations, ideally 
as case control studies. The nature of association of migraine and CD 
remains contentious (Cicarelli, Della Rocca et al. 2003; Gabrielli, Cremonini et 
al. 2003) and further investigation into putative association is recommended. 
On the basis of this study, I suggest that the role of pathological mechanisms 
should be further explored such as the role of malabsorption of biopterin 
compounds and trace vitamins and the role of altered auto-immunity and in 
particular susceptible HLA groups.  
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Chapter 6 - A novel anti-spinal antibody 
in patients with gluten sensitivity 
  87 
  
6.1 Aim 
I aimed to investigate the presence of anti-neuronal antibodies in serum of 
patients with confirmed gluten sensitivity namely patients with established DH 
and CD. 
 
6.2 Introduction 
The association of CD with a variety of neurological disorders has been 
frequently described but whether a specific neurological association occurs 
with CD remains unproven. The aetiology of these associations is unclear. 
Gluten neurotoxicity has been postulated as a mechanism to explain the 
apparent association of gluten sensitivity with various neurological disorders 
described prominently with FHUHEHOODU DWD[LD µJOXWHQ DWD[LD¶ (Hadjivassiliou, 
Grunewald et al. 1998). It has been suggested that the basis of this is 
immunological. 
 
Enteropathy in classical CD is presumed to be immunological and T-cell 
mediated. Immune mechanisms such as deposition of circulating immune 
complexes in other organs are a likely cause of extra-intestinal manifestations 
of gluten sensitivity. For example, the blistering skin condition, DH, also a 
gluten-sensitive disease, is characterised by IgA deposition in papillary 
dermis. Previous chapters have demonstrated a low prevalence of idiopathic 
neurological abnormalities in patients with DH and CD with no evidence of 
immune-mediated neurological damage. The relationship between gluten 
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exposure and neurological abnormality is questionable, particularly with 
regards to immune-mediated neurological damage. 
 
6.3 Methods  
6.3.1 Patients 
Thirty-five patients with biopsy-proven DH were identified from Dermatology 
RXWSDWLHQWFOLQLFVDW6W0DU\¶V+RVSLWDO/RQGRQDQG4XHHQ¶V0HGLFDO&HQWUH
Nottingham. Fifty-three patients with biopsy-proven CD were identified from a 
CD outpatient clinic at the Derbyshire Royal Infirmary, Derby. Patients 
underwent thorough neurological examination and casenote review. Their 
FOLQLFDOIHDWXUHVDUHGHVFULEHGLQWKHSUHYLRXVFKDSWHU7KHVXEMHFWV¶FRQVHQW
was obtained according to the declaration of Helsinki and ethical approval was 
obtained from the Ethics Committees of both institutions. Serum samples 
were stored at -Û&XQWLOUHTXLUHG 
6.3.2 Controls 
Thirty random anonymous blood donors, 22 non-CD patients with idiopathic 
neurological disorder (ataxia and peripheral neuropathy) and 30 patients with 
psoriasis were used as controls.  
6.3.3 Antineuronal antibody Western Immunoblotting 
The presence of anti-neuronal antibodies was investigated in the serum of the 
gluten-sensitive group (CD and DH) as well as the control patients. Samples 
and controls were diluted 1:300. Proteins extracted from guinea pig brain were 
stored at -Û& EHIRUH XVH 6DPSOHV RI WKHKRPRJHQDWH ZHUH UHGXFHG DQG
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denatured in lithium dodecyl sulphate buffer (Invitrogen) at 6Û& IRU 
minutes. A total of ȝJRISURWHLQZDV ORDGHGRQWRD WR%LV-Tris gel 
(Invitrogen) and electrophoresed. The proteins were blotted onto nitrocellulose 
(Sartorius, Epsom) and blocked by incubation in a 2% solution of powdered 
FRZ¶VPLON IRUKRXUV6DPSOHVZHUHGLOXWHGDSSOLHG WR WKHEORWDQG
LQFXEDWHGRYHUQLJKWDWÛ&7KHQLWURFHOOXORVHZDVZDVKHd with 10 changes of 
0.9% saline containing 0.2% milk proteins and Tween. The blot was incubated 
for 2 hours with rabbit anti-human IgG conjugated with horseradish peroxide 
diluted at 1:1000 (Dako, Cambridge, UK). After washing, the substrate 4-
chloro-1-naphthol (Sigma) was added and the blot was allowed to develop for 
15 minutes. This technique is routinely used in the Neuroimmunology 
Laboratory, Institute of Neurology, Queen Square for identifying antibodies 
associated with paraneoplastic disorders. 
 
The same method was used to examine binding to spinal cord using human 
spinal cord extract. 
 
6.4 Results 
Fourteen of the 35 DH patients were controlled by a GFD alone although 
compliance may have been poor in a proportion of these patients. Fifteen 
patients required dapsone as well as adhering to a partial GFD. Six patients 
chose not to take a GFD and the rash was controlled with dapsone alone. 
Neurological abnormalities that were identified in the DH cohort were chorea 
(1), essential tremor (1) and migraine (2).  
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53 patients with confirmed CD were identified with mean age 48 years (range 
18-88). Twenty-two patients had newly diagnosed CD (awaiting or newly 
started on GFD) with mean age 53 (range 21-88). Thirty-one patients had 
established disease (GFD longer than 1 year) with mean age 45 (range 18-
81). Patients already on GFD had received this for a mean of 11 years (range 
1-26). Nine neurological abnormalities that were identified in 16 of 53 patients 
were epilepsy (1), restless legs syndrome (1), carpal tunnel syndrome (1), 
EHQLJQ IDVFLFXODWLRQV  PXOWLSOH VFOHURVLV  6\GHQKDP¶V FKRUHD 
cluster headache (1), diabetic neuropathy (2) and migraine (7).  
6.4.1 Laboratory Findings 
On testing for binding to guinea pig brain, the only positive finding was in the 
DH patient with chorea who had equivocally positive Anti-Hu antibodies. An 
unexpected finding was a novel anti-spinal antibody detectable from 
peripheral blood in over 50% (18/34) of the subjects with DH. On Western 
blot, this antibody reacted with a protein of 74 kDa from an extract of human 
spinal cord. This antibody was not found in CD patients, non-CD patients with 
idiopathic neurological disorder, psoriasis patients or blood donor controls. 
6.5 Discussion 
CD is an immune-mediated disorder and as such an immune mechanism for 
neurological illness in patients with proven gluten sensitivity is an attractive 
one. Evidence for this is conflicting particularly the role of anti-neuronal 
antibodies. One criticism of previous studies is a poor understanding of the 
accepted pathogenic mechanisms of the immune reaction that occurs with CD 
and DH. In fact these are not completely understood. We know that TTG 
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seems to be the target self-antigen for endomysial antibodies in CD and 
catalyses the critical deamidation of gliadin (the toxic fragment of gluten, the 
protein fraction of wheat) which strengthens its recognition by HLA-restricted 
gut-derived T cells. A recent study demonstrated that gliadin was directly 
bound to TTG in duodenal mucosa of coeliacs and controls, and that 
circulating TTG-autoantibodies were able to recognize and immunoprecipitate 
the TTG-gliadin complexes (Ciccocioppo, Di Sabatino et al. 2003). 
Volta and co-workers (Volta, De Giorgio et al. 2002) analysed a large series of 
adult CD pts with a variety of neurological disorders in comparison to CD 
patients without neurological disorder. They found antineuronal antibodies in 8 
of a heterogeneous group of 13 patients with neurological disorder ranging 
from patients with non-specified memory deficit to myotonic dystrophy to 
multiple sclerosis as well as biopsy-proven CD. However they did not make 
any comparison to a control neurological population and hence the 
significance of this finding is questionable. They demonstrated a nuclear and 
cytoplasmic staining of Purkinje cells as well as a nuclear staining of the 
granular layer of neurones. They did not detect any difference between 
prevalence of antineuronal antibodies to the enteric nervous system in 
patients and controls. They further claimed that these patients improved on 
GFD when in fact some of these conditions usually have no clear treatment 
e.g. moyamoya that was said to improve with Aspirin and GFD. Overall this 
study contributed little other than to say that there was some non-specific 
immune reaction in the nervous system (central and enteric) of a proportion of 
a small group of patients with CD and neurological illness. One interesting 
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finding was that these antibodies disappeared a year following GFD and this 
does merit further attention.  
One study has suggested that the presence of circulating Purkinje cell 
antibodies in the serum of patients with gluten ataxia provides evidence for an 
immune pathogenesis. The same research has shown that antigliadin 
antibodies cross react with Purkinje cells, suggesting the sharing of common 
epitopes between gliadin proteins and Purkinje cells (Hadjivassiliou, Boscolo 
et al. 2002).  
 
DH, the classical extra-intestinal manifestation of gluten sensitivity, is not fully 
understood but what evidence exists suggests precipitates of IgA in the 
papillary dermis containing epidermal transglutaminase. Epidermal and tissue 
transglutaminases in DH and CD respectively are highly homologous. Cross-
reactivity of the two antibodies may explain why patients with either DH or CD 
will have antibodies to both these enzymes but in DH the skin manifestation 
occurs because epidermal transglutaminase antibodies produced are of high 
avidity and affinity (Karpati 2004). This is an intriguing finding and further 
supportive evidence would be the demonstration of TTG antibodies in patients 
with neurological gluten sensitivity, specifically a similarly homologous 
antibody, a neuronal transglutaminase antibody. 
 
A novel anti-spinal antibody was seen only in a high proportion of patients with 
DH. It has been shown that neurological disorders have a low prevalence in 
this cohort. No cases of idiopathic cerebellar ataxia were detected. The first 
patients with CD and neurological abnormality described in detail had 
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predominantly sensory ataxia (Cooke and Smith 1966). The unexpected 
discovery of a novel spinal antibody in DH patients may suggest a potential 
mechanism for the previously reported increased association of sensory 
ataxia in patients with established gluten sensitivity. However none of the 
study patients had clinical evidence of dorsal column dysfunction, which may 
suggest that an additional co-factor (possibly a trace vitamin) is required for 
the development of symptoms. Malabsorption of some vitamins has been 
investigated but the role of a number of trace elements has not been 
elucidated. 
 
DH patients have greater exposure to gluten than CD patients because they 
often have no gastrointestinal symptoms and their dermatological symptoms 
are more easily treated with dapsone. The absence of this spinal cord 
antibody in patients with CD may reflect this. However, the presence of this 
spinal antibody in DH patients appears to be irrespective of their gluten 
consumption status. Moreover 22/53 of our CD patients had recent or ongoing 
gluten consumption (i.e. newly-diagnosed CD patients). It would have followed 
that this spinal antibody would be found in the newly-diagnosed CD patients 
also. Therefore this antibody does not appear to be related to gluten 
exposure. 
 
Further characterisation of this novel spinal antibody is required. Firstly this 
finding needs to be validated. The next step is immunohistochemistry. 
Preliminary data on a proportion of these patients suggests binding to dorsal 
column neurones although this finding needs to be confirmed across all the 
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samples (Personal communication Prof F Scaravilli). Finally the relevant 
antigen will need to be identified. This may be a chance finding in a cohort of 
patients with autoimmune disease and subsequently a link to gluten 
immunoreactivity would need to be demonstrated.  
 
In conclusion, whilst it is possible that this spinal cord antibody may be an 
explanation for sensory ataxia in patients with gluten sensitivity, this finding 
requires replication and further clarification particularly in terms of an 
additional co-factor for the development of symptoms. Alternatively these 
patients may simply be exhibiting some non-specific immune reaction in the 
nervous system as an epiphenomenon. 
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Chapter 7 ± Prevalence of gluten 
sensitivity in multiple sclerosis 
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7.1 Aim 
I aimed to investigate seropositivity for AGA, TTG and EMA in an unselected 
group of multiple sclerosis (MS) patients in order to investigate prevalence of 
occult gluten sensitivity. 
 
7.2 Introduction 
Improved screening for IgA antibodies associated with CD i.e. ARA, AGA, 
EMA and TTG, has improved the detection of CD in recent years. However, 
IgG class antibodies, have poor disease specificity (Lagerqvist, Ivarsson et al. 
2001). AGA is an anti-wheat protein antibody, which, like other food 
antibodies (e.g. anti-ovalbumin), especially of IgG class, is not disease-
specific.  
7.2.1 A putative association between ataxia and gluten sensitivity 
Associations between AGA positivity (as distinct from CD) and cerebellar 
ataxia have been reported (Hadjivassiliou, Grunewald et al. 1998), with 
speculation that the ataxia is gluten induced. Some investigators have further 
suggested that a GFD is likely to be of benefit in idiopathic ataxic syndromes. 
However AGA positivity is also seen in a number of ataxias known to have a 
non-gluten sensitive pathogenesis including autosomal dominant cerebellar 
ataxia and multiple system atrophy (Abele, Burk et al. 2002).  
7.2.2 Multiple sclerosis and occult gluten sensitivity 
Previous researchers have investigated the role of a GFD in the treatment of 
MS and found no benefits (Jones, Pallis et al. 1979). The relapsing-remitting 
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natural history of MS can make interpretations very difficult. Two patients seen 
in the Neurology outpatient clinic (1 at the Derbyshire Royal Infirmary, Derby 
and the other at the 4XHHQ¶V 0HGLFDO &HQWUH 1RWWLQJKDP with MS-like 
disease were identified who were incidentally discovered to have occult CD.  
7.2.2.1 Patient 1 
A 24 year-old woman presented with diplopia, left retro-orbital pain and right 
arm and leg weakness. Four months earlier she had developed lumbar and 
buttock pain and paraesthesia affecting the whole left lower limb with urinary 
urgency and incontinence, which resolved without treatment. On examination 
she had left sixth and seventh nerve palsies, ataxia and a mild right 
hemiplegia. A clinical diagnosis of MS was made. MRI of the lumbar spine 
was normal. MRI scan of the brain and spinal cord showed an ill-defined high 
signal area in the left side of the pons  (Figure 7.1). CSF protein, glucose and 
cell count were normal. There were no oligoclonal bands in the CSF but IgG 
levels were raised suggestive of intrathecal synthesis. Subsequently, routine 
autoantibody screening revealed positive ARA. She was therefore screened 
for GSE and was found to have strongly positive IgA EMA, IgA anti-TTG and 
IgG AGA in the serum. IgA AGA was negative. Interestingly her CSF was also 
positive for IgA anti-TTG. A subsequent small bowel biopsy was characteristic 
of GSE and she was commenced on a GFD.  
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Figure 7.1 T2 weighted MRI of the brain showing high signal area in left side 
of pons in Patient 1. 
 
7.2.2.2 Patient 2 
A 26 year-old woman was admitted with gradual onset of slurred speech, 
clumsiness and weakness of the right side. Examination revealed cerebellar 
dysarthria, right-sided weakness, and ataxia. MRI scan of the brain showed a 
high signal lesion in the right parietal lobe adjacent to the posterior horn of the 
right lateral ventricle. Antibody screening revealed strongly positive IgA ARA 
and IgA EMA. IgA and IgG AGA were negative. A duodenal biopsy confirmed 
GSE and she commenced GFD with correction of the previous borderline low 
vitamin B12. She was subsequently found to have negative oligoclonal bands 
in her CSF. Three months later she developed further mild right-sided 
weakness and subjectively altered sensation of the right-sided limbs and 
trunk. MRI of the cervical spine showed two high signal lesions in the cervical 
cord at the level of C2/3 and C4/5 on T2 weighting (Figure 7.2). 
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Figure 7.2 T2 weighted MRI of the cervical cord of Patient 2 showing two high 
signal lesions at C2/3 and C4/5 
 
Both patients were acutely treated with 1g of IV Methylprednisolone daily for 
three days and had experienced no further neurological episodes at the time 
of writing.  
 
7.3 Methods  
Patients were recruited IURPJHQHUDOQHXURORJ\DQG06FOLQLFVDWWKH4XHHQ¶V
Medical Centre, Nottingham and the Derbyshire Royal Infirmary, Derby. The 
VXEMHFWV¶ FRQVHQW ZDV REWDLQHG DFFRUGLQJ WR WKH GHFODUDWLRQ RI +HOVLQNL DQG
ethical approval was obtained from the Ethics Committees of both institutions. 
 
Forty-nine patients with MS (33 female) were recruited. Thirty-eight had 
relapsing-remitting disease, 10 had secondary progressive disease and 1 had 
primary progressive disease. In all cases a Consultant Neurologist with an 
interest in demyelinating disease made the diagnosis of MS. None of the 
patients had specific symptoms suggestive of GSE, any suggestive family 
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history or features suggestive of malabsorption. Thirty random anonymous 
blood donors (15 female) were used as serological controls. 
7.3.1 Immunological testing 
AGA (IgG and IgA) and IgA anti-TTG were detected by enzyme linked 
immunosorbent assay (ELISA), according to the manufacturer¶s instructions 
(Orgentec Diagnostika GmbH, Mainz, Germany). These assays were carried 
out courtesy of Dr RJ Lock, Clinical Scientist and Dr. DJ Unsworth, Consultant 
Immunologist at the Department of Immunology and Immunogenetics, 
Southmead Hospital, Bristol. 
7.3.2 Statistical testing 
'DWDZDVDQDO\VHGE\)LVKHU¶V([DFW7HVWWRFRPSDUHSDWLHQWVDQGFRQWrols. 
7.4 Results 
IgG and IgA AGA were found in 6/49 (12%) and 3/49 (6%) patients, 
respectively, similar to controls (13% and 7%)(p=1.00 and 1.00 respectively). 
IgA anti-TTG was found in 3/49 patients, again similar to controls (0/30; 
p=0.466). Of these, two were weakly positive and subsequently found 
negative for IgA EMA. Serum from one patient was strongly positive for IgG 
and IgA AGA and strongly positive for IgA anti-TTG and EMA, consistent with 
CD. This patient had no gastrointestinal symptoms and declined small bowel 
biopsy. One control subject was positive for IgG and IgA AGA, but negative 
for anti-TTG and EMA.  
 
 MS patients 
(n=49) 
Controls (n=30) P value 
)LVKHU¶V([DFW
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Test) 
IgA AGA 3 (6%) 2 (7%)    1.00 
IgG AGA 6 (12%) 4 (13%)  1.00 
IgG anti TTG 3 (6%) 0 (0%) 0.466 
IgA EMA 0 (0%) 0 (0%)  
 
Table 7.1 Comparison of the incidence of AGA, TTG and EMA antibodies in 
serum of multiple sclerosis (MS) patients and controls. 
7.5 Discussion 
Only one MS patient (2%) in this study had strongly positive IgA anti-TTG and 
EMA and it is likely that this patient has occult GSE. This patient had no 
enteric symptoms and declined small bowel biopsy. CD is common in the 
general population with a prevalence rate estimated at 1% in the UK. Finding 
one patient among a cohort of 49 with occult CD is therefore likely to be a 
chance association. 
There is strong historical evidence that occult gluten sensitivity does not play 
a role in the development of MS.  In the 1970s, there was great interest in the 
possibility of treating multiple sclerosis with a gluten free diet. In 1974, 
Matheson reported success with a GFD in MS (Matheson 1974) although little 
was known about the intestinal morphology or antibody status of the patients 
investigated. Lange and Shiner (Lange and Shiner 1976) showed that two of 
12 MS patients had abnormal bowel mucosa. However, in 1979, Jones et al 
(Jones, Pallis et al. 1979) studied jejunal biopsies in 14 patients with MS, 
finding no serological or morphological evidence of CD to support the use of a 
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GFD in MS. Other researchers supported this finding (Bateson, Hopwood et 
al. 1979; Hewson 1984; Hunter, Rees et al. 1984). Mainstream neurologists 
have largely abandoned the use of a GFD in MS. Despite this, some MS 
literature and Internet sites continue to cite the usefulness of GFD and 
anecdotally a few of our patients claimed to have heard of the diet for disease 
modification.  
 
In the two patients described with a MS-like illness, occult CD was only 
suspected following serological clues. Interestingly one patient had positive 
TTG antibodies in the CSF (not previously reported) raising the question of a 
pathogenic role for TTG in the development of CNS inflammation.  
 
There have been varying reports of immune-mediated damage to the CNS 
demonstrable in the CSF of patients with gluten sensitivity. Ghezzi et al 
(Ghezzi, Filippi et al. 1997) described a patient with CD who developed a 
relapsing-remitting brainstem and cerebellar syndrome following an intestinal 
relapse. Serial MRI scanning revealed multiple enhancing lesions. CSF 
examination, initially normal, subsequently showed the presence of oligoclonal 
IgG bands and an increased CSF/serum albumin ratio indicating damage to 
the blood-brain barrier. The authors suggested an inflammatory process as an 
explanation for neurological complications of patients with CD. It could be 
argued that this patient had coincidental CD and MS. However, it is 
QRWHZRUWK\WKDWWKLVSDWLHQW¶VERZHOGLVRUGHUIDLOHGWRUHVSRQGWRD*)'ZKLFK
raises diagnostic uncertainties. 
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Chinnery and co-workers (Chinnery, Reading et al. 1997) reported a patient 
with CD and Ramsay Hunt syndrome (progressive myoclonic ataxia and 
epilepsy) with IgG and IgA AGA found in the CSF. They suggested that this 
finding in the absence of evidence of a generalised breakdown in the blood-
brain barrier supported an autoimmune aetiology and local production of AGA 
within the CNS. A subsequent study looking for positive gliadin antibodies in 
serum of patients with sporadic ataxia found no inflammatory changes in the 
CSF of these patients that would account for the neurological symptoms 
(Burk, Bosch et al. 2001). However, an earlier description by Bernier and 
colleagues of two women with CD and sensory ataxic polyneuropathy showed 
a meningeal inflammatory reaction in the CSF of one of the cases (Bernier, 
Buge et al. 1976). Nerve and muscle biopsies showed inflammation with 
selective micro-vasculitis in both patients possibly suggesting a mechanism of 
circulating immune complexes related to CD.  
 
Both patients described above admittedly had a slightly atypical phenotype for 
MS. It seems more likely that the presence of anti-TTG in the CSF of this 
patient was secondary to leakage through a damaged blood brain barrier 
rather than implying a pathogenic role for TTG in the development of CNS 
inflammation. However I cannot exclude the possibility that these two patients 
have developed an inflammatory disease of the CNS associated (directly or 
indirectly) with gluten sensitivity. 
 
In 1996, it was reported that 57% of patients with cryptogenic neurological 
disorders were AGA seropositive (IgG and or IgA) compared to 5% of patients 
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with neurological diseases of known aetiology, and 12% of normal controls 
(Hadjivassiliou, Gibson et al. 1996) $ QHZ V\QGURPH ³JOXWHQ DWD[LD´ ZDV
proposed, implying a gluten-mediated immunopathology largely on the basis 
of AGA seropositivity.  
 
The use of AGA antibodies, particularly IgG AGA, as a screening test for 
gluten sensitivity remains controversial. Specificity for coeliac disease (gluten 
enteropathy) is low in comparison with IgA ARA, AEA and anti-TTG. AGA 
antibodies have been found in a number of conditions such as IgA 
nephropathy (Rostoker, Laurent et al. 1988). In addition the predictive value of 
a positive result when applied to the likelihood of developing histopathological 
features of CD in the gut has been shown to be 28% for IgA AGA in one study 
(Valdimarsson, Franzen et al. 1996) and 0 % for IgG AGA in another(Collin, 
Helin et al. 1993). The other difficulty when applying screening to specific 
populations is that occult gluten sensitivity (as defined by AEA positivity) is 
common and has been shown to have a prevalence rate of as high as 1:82 
individuals in certain populations (Cook, Burt et al. 2000). Recent published 
reports have suggested that there is a high prevalence of AGA positivity in 
patients with various genetic (Bushara, Goebel et al. 2001) and sporadic 
ataxias (Abele, Burk et al. 2002) of known aetiology. This may indicate that 
AGA positivity is an epiphenomenon, unrelated to neuronal damage.  
 
16% of the MS patients and 17% of the blood donor controls had AGA, mainly 
of IgG isotype, reflecting the long established poor disease specificity for IgG 
AGA. IgG AGA seen in other neurological populations should therefore be 
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interpreted with caution. This is an important observation as some 
investigators have suggested that a GFD is likely to be of benefit in idiopathic 
ataxic syndromes. Convincing proof however has not been presented, and 
this data suggests that this is a false premise. 
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Chapter 8 - Prevalence of gluten 
sensitivity in neurological populations 
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8.1 Aim 
I aimed to study the association between gluten sensitivity, HLA status and 
neurological dysfunction in neurological patients with ataxia, and neuropathy 
by using assays of anti-TTG, EMA, AGA as well as other food antibodies. MS 
patients were used as neurological controls. 
 
8.2 Introduction 
As shown in the previous chapter, in MS patients there is a high rate of AGA 
positivity and this is a non-specific finding. This suggests that there needs to 
be a more cautious interpretation of AGA positivity in the context of 
neurological patients where the role of gluten in aetiology remains uncertain 
and in whom a GFD is thus unlikely to be a helpful intervention.  
 
Associations between AGA positivity, particularly in combination with a HLA 
DQ2 haplotype, and cerebellar ataxia have been reported. Hadjivassiliou and 
co-workers have proposed that a large proportion of patients with cryptogenic 
ataxia has occult gluten sensitivity (Hadjivassiliou, Grunewald et al. 2003). 
They have also suggested that the majority carried the HLA haplotype DQw2, 
FRLQLQJWKHWHUP³JOXWHQDWD[LD´7KLVLVDSRWHQWLDOO\LPSRUWDQWREVHUYDWLRQDV
it suggests that simple dietary manipulation (gluten restriction) provides a 
potential treatment for a condition hitherto thought of as inexorably 
progressive. Some studies have supported these initial findings. However, this 
hypothesis has been challenged because AGA positivity is also seen in a 
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number of ataxias with a known cause including autosomal dominant 
cerebellar ataxia, multiple system atrophy and alcohol-related cerebellar 
damage (Abele, Burk et al. 2002). A recent study showed a prevalence of 
AGA positivity in 27% and 37% of patients with sporadic and autosomal 
dominant ataxias (ADCA) respectively (Bushara, Goebel et al. 2001). This 
group of researchers has also demonstrated a high AGA positivity in patients 
with +XQWLQJWRQ¶VGLVHDVH(Bushara, Nance et al. 2004). 
 
One possible interpretation is that AGA positivity might be an epiphenomenon 
associated with cerebellar damage. All these studies have been heavily reliant 
on AGA positivity as a screening tool and have inferred that the presence of 
these antibodies is synonymous with clinical gluten sensitivity. This is 
contested, particularly as in classical gluten sensitive enteropathy it is well 
recognised that anti-wheat protein antibodies and other simple food antibodies 
such as anti-ovalbumin and anti-casein are not pathognomonic. In contrast, in 
GSE, IgA autoantibodies including ARA, EMA and anti-TTG are highly specific 
and sensitive (Unsworth 1996; Lock, Pitcher et al. 1999).  
 
8.3 Methods 
8.3.1 Patients 
Over a two-year period, patients with idiopathic ataxia (27) and peripheral 
neXURSDWK\  DWWHQGLQJ VSHFLDOLVW FOLQLFV DW WKH 4XHHQ¶V 0HGLFDO &HQWUH
Nottingham and the Derbyshire Royal Infirmary, Derby were prospectively 
identified. In these clinics 5400 new neurology referrals are seen annually, 
from a background population of 2 million people.  
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In the ataxia group demyelination, alcohol toxicity, prolonged use of 
anticonvulsant medication and viral or paraneoplastic causes were excluded. 
None of the patients had evidence of multiple system atrophy (MSA) type C. 
All the patients had 05, RI WKH EUDLQ DQG DOO ZHUH VFUHHQHG IRU)ULHGUHLFK¶V
ataxia and SCA 1, 2, 3, 6 and 7. However, during the course of investigation 
seven patients were discovered to have either a strong family history of ataxia 
(3 cases) or the presence of a known geQHWLFGHIHFW )ULHGUHLFK¶VDWD[LD - 2 
cases, SCA 3 - 1 case, SCA 6 - 1 case). In the subsequent analysis, these 
were utilised as an internal disease control group (Group 1), leaving 20 
remaining cases with idiopathic ataxia (Group 2).  
 
In the peripheral neuropathy group (Group 3) diabetes, alcohol excess, drug 
toxicity, paraproteinaemia, systemic vasculitis, vitamin/nutritional deficiencies 
and other general medical disorders (connective tissue disorders, diabetes 
etc) were excluded by appropriate investigation. In all cases the diagnosis 
was confirmed electrophysiologically. Twenty-four were axonal and eight 
demyelinating in nature. 
 
All patients gave informed consent and the study was approved by the local 
Ethics Committees. 
8.3.2 Immunological and genetic testing 
These assays were carried out courtesy of Dr RJ Lock, Clinical Scientist and 
Dr. DJ Unsworth, Consultant Immunologist at the Department of Immunology 
and Immunogenetics, Southmead Hospital, Bristol. 
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8.3.2.1 Antibody Assays 
AGA (IgG and IgA) and IgA TTG were detected by enzyme linked 
LPPXQRVRUEHQW DVVD\ (/,6$ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV
(Orgentec Diagnostika GmbH, Mainz, Germany). For other food antigen 
ELISAs, 100Pl volumes of Elactoglobulin or ovalbumin (Sigma, Poole UK) at 
20Pg/ml in carbonate/bicarbonate buffer were used to coat the plates 
overnight at 40C. All further incubations used 100Pl volumes, at room 
temperature, for one hour. All wash steps used 0·05% Tween/PBS repeated 
WKUHH WLPHV $IWHU ZDVKLQJ SDWLHQW¶V VHUXP GLOXWHG WR  in 0·05% 
Tween/PBS was applied to duplicate wells. After a further wash, 100 Pl of 
either alkaline phosphatase conjugated goat anti-human IgA (Dako Ltd., Ely, 
UK) diluted 1 in 500 or alkaline phosphatase conjugated goat anti-human IgG 
(Dako) diluted 1 in 500 in 0·05% Tween/PBS was added to each well. Sigma 
VXEVWUDWHZDVXVHGDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGWKH
optical density (OD) read at 405nm. 
 
Cut offs for in house ELISA assays, expressed as optical density were 
determined by the technique of probability plotting (Lock and Unsworth 2003). 
 
8.3.2.2 Class II antigens 
DNA was extracted using the Whatman Bioscience Genomic DNA Purification 
6\VWHP DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV HLA-DR Polymerase 
Chain Reaction using sequence specific primers (PCR-SSP) was adapted from 
Olerup and Zetterquist (Olerup and Zetterquist 1992). HLA-DQ PCR-SSP was 
adapted from Olerup et al (Olerup, Aldener et al. 1993). PCR-SSP samples 
were subjected sequentially to 5 cycles of PCR (96°C for 25s, 70°C for 45s, 
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72°C for 45s), 22 cycles (96°C for 25s, 65°C for 50s, 72°C for 45s) and 4 cycles 
(96°C for 25s, 55°C for 60s, 72°C for 120s).  PCR-SSP products were 
electrophoresed through a 1.5% agarose gel at 300v for 20 min. 
 
8.3.3 Statistics 
Data was analysed using the Binomial test (to assess differences between the 
WHVW SRSXODWLRQ DQG UHIHUHQFH GDWD $129$ RU )LVKHU¶V ([DFW 7HVW DV
appropriate. 
 
8.4 Results 
Table 8.1 shows the median age, age range, male to female ratio and 
antibody/HLA status for the three groups. Groups 2 and 3 were not 
significantly different in mean age (p=0.11) or gender distribution (p=0.31). 
Group 1, found incidentally during the study, is very small and statistical 
analysis was considered inappropriate. The data do illustrate however that 
food antibodies of all types are also found in hereditary ataxia. High 
prevalence of IgG antibodies particularly was noted, ranging from 15-30%. No 
IgA TTG was detected in any of the groups. 
 
 Hereditary 
Ataxia 
(Group 1) 
Idiopathic 
Ataxia 
(Group 2) 
 
Peripheral 
Neuropathy 
(Group3)  
Number 7 20 32 
Male:Female 4:3 15:5 20:12 
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Median Age (range) 
(years) 
51 (36-70) 62 (34-80) 70 (32-86) 
Any AGA (IgG or IgA) 3 (43%) 
 
8 (40%) 
[0·132] 
11 (34%) 
[0·192] 
Any AGA and HLA DQ2 
positive (#) 
2/4 (50%) 4/8 (50%) 5/11 (45%) 
Any anti-lactoglobulin 
(IgG or IgA) 
2 (29%) 
 
6 (30%) 
[0·156] 
8 (25%) 
[0·224] 
Any anti-lactoglobulin 
and HLA DQ2 positive (#) 
1/1  2/6 (33%) 2/6 (33%) 
Any anti-ovalbumin (IgG 
or IgA) 
3/7 (43%%) 
 
5 (25%) 
[1·000] 
10 (31%) 
 
Any anti-ovalbumin and 
HLA DQ2 positive (#) 
2/3 (67%) 2/5 (40%) 3/9 (33%) 
IgA anti-TTG 0 
[1·000] 
0 
[1·000] 
0 
[1·000] 
HLA DQ2 (*) (#) 4/6 (67%) 
[0·880] 
9/19 (47%) 
[0·894] 
11/28 (39%) 
[0·432] 
HLA DQ8 (**) (#) 2/6 (33%) 
[0.606] 
4/19 (21%) 
[0.937] 
5/28 (18%) 
[0.815] 
 
Table 8.1 Clinical details and antibody/HLA status for the three groups 
(Hereditary ataxia, idiopathic ataxia and peripheral neuropathy). 
P values (in square brackets) calculated by comparison with peripheral 
neuropathy control population except (*) and (**) where P values calculated 
against an English population mean of 48·5 and 18.3.  
N.B. DNA samples were not available for all cases (#) 
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8.5 Discussion 
There was a striking absence of serological evidence for occult CD in cases 
with idiopathic ataxia or neuropathy. No cases were positive for IgA anti-TTG. 
This is very different indeed to the initial reports of up to 25% by some other 
groups (Hadjivassiliou, Gibson et al. 1996; Pellecchia, Scala et al. 1999; 
Luostarinen, Collin et al. 2001), although a lower prevalence of biopsy-proven 
CD has been reported by one group (Burk, Bosch et al. 2001). By contrast 
food antibodies, (wheat gliadin, hens¶HJJDOEXPLQFRZV¶PLON ODFWRJOREXOLQ
particularly of IgG type were common in patients with idiopathic neuropathy or 
ataxia. These data support and extend the findings of Abele et al showing a 
significant increase in AGA in ataxia (Abele, Burk et al. 2002) This might 
simply reflect an age-related phenomenon or it may alternatively imply a 
general heightened responsiveness of the gut immune system in these 
individuals or some problem with gut permeability or inflammation.  
 
Again in contrast to the findings of others there was no over-representation of 
HLA DQ2 or DQ8, in these cases (Hadjivassiliou, Grunewald et al. 1998; 
Burk, Bosch et al. 2001). In other defined gluten sensitive disorders (CD, DH) 
HLA DQ2 is found in >95% of cases (Zubillaga, Vidales et al. 2002). 
Furthermore, in this study, patients with the HLA DQ2 haplotype in this study 
were no more likely to have AGA than those without (p=0·606).  
 
Of note, very few patients were found who meet the inclusion requirements of 
Hadjivassiliou et alIRU³JOXWHQDWD[LD´:KHUHDVWKH\GHVFULEHDJURXSRI
patients with idiopathic ataxia in 4 years who had AGA (Hadjivassiliou, 
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Grunewald et al. 1998), 23 of whom were also HLA DQ2 positive, this study 
only identified 4 patients in 2 years who meet these criteria, i.e. only one-third 
of the incidence assuming that the Neuroscience Centres in Nottingham and 
Sheffield serve a similar sized population. Ascertainment bias cannot be ruled 
out as a contributing factor to the differences in the two sets of data. 
 
These results raise a number of interesting issues with regard to the 
QRVRORJLFDO VWDWXV RI ³JOXWHQ DWD[LD´ , GLVDJUHH ZLWK WKH QRWLRQ WKDW $*$
seropositivity per se is synonymous with gluten sensitivity whether it be in 
neurological or other patient populations. 40% of the patients screened in this 
study have AGA positivity, within which must be contained the 10-15% of 
healthy individuals who must also have AGA. In the classical or prototypic 
gluten sensitive diseases (CD and dermatitis herpetiformis) these antibodies 
lack specificity and alternative antibody disease markers (IgA anti-tissue 
transglutaminase) are utilised (Wills and Unsworth 2002). An analogous 
situation arises with IgE class antibodies that may be detected in person 
without any allergic symptoms. 
 
Whether AGA positivity mirrors, via immune mediated mechanisms, gluten 
induced neurological damage is debated. I contend that AGA in hereditary 
ataxias must be an epiphenomenon. 7KHPRVWDSSHDOLQJDVSHFWRIWKH³JOXWHQ
DWD[LD´ K\SRWKHVLV LV WKDW LW RIIHUV WKH SURVSHFW RI DQ H[FOXVLRQ GLHW DV D
realistic therapeutic possibility. This non-blind study needs confirmation from 
studies in other centres. This data so far do not support the view that 
idiopathic ataxia is a gluten-related disorder and by extension nor does it 
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support the introduction of GFD. It is not known whether dietary restriction of 
milk and egg products might have a beneficial effect on similar groups. 
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Chapter 9 ± Discussion and 
conclusions 
  117 
 
9.1 Summary of Findings 
The overall objective of my research was to investigate the hypothesis of the 
existence of a gluten sensitive neurological disease. This thesis aimed to look 
at the association of gluten sensitivity and neurological illness from a number 
of viewpoints: 
 The features and prevalence of neurological disorders associated with 
gluten sensitive enteropathy, 
 The prevalence of gluten sensitivity in patients with neurological 
disorders, 
 Possible mechanisms to account for the apparent association between 
neurological disorders and gluten sensitivity.  
 
Chapter 1 summarised CD, its epidemiology, pathogenesis, complications, 
associations and treatment. This contextualised CD as a gluten-sensitive 
enteropathy of multi-factorial aetiology. Exposure to gluten and a genetic 
predisposition are the two pre-requisites for development of the disease. DH, 
manifesting as a dermatological condition, was described as a useful model of 
another gluten sensitive syndrome.  
Chapter 2 reviewed the literature on neurological conditions proposed to have 
an association with gluten sensitivity including possible aetiology, pathological 
findings and potential treatments.  
The first study, described in Chapter 3, investigated patients utilising the 
BNSU as well as from personal case series. This revealed that CD with 
coexistent neurological dysfunction is rarely reported in a neurological setting. 
The 18 cases reviewed were heterogeneous and included epilepsy, 
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myelopathy, axonal neuropathy and migraine. No occipital calcifications were 
reported in patients with epilepsy. No cases of gluten ataxia were reported.  
The second study, described in Chapter 4, investigated the prevalence of 
neurological disorders in an unselected group of patients with CD with 
particular emphasis on epilepsy. A combination of patient interviews and 
retrospective casenote review found 54 neurological disorders in 177 patients 
in a cohort of 801 CD patients. These included stroke (2.9%), migraine 
(2.7%), epilepsy (2.6%) and carpal tunnel syndrome (2.0%). Of 21 patients 
with a history of epileptic seizures, only nine (1.1%) had active epilepsy. No 
specific epileptic syndrome was identified and a causal relationship between 
CD and active epilepsy seems unlikely on the basis of these observations.  
In the third study contained in Chapter 5, careful neurologist-led assessment 
of two cohorts of patients with DH and CD found a prevalence of idiopathic 
neurological abnormalities of 11% and CD 25% respectively. DH and CD 
share common immunopathological and genetic mechanisms. However, DH 
patients have potentially greater gluten exposure than CD patients as they 
tend to present later and often continue to consume gluten in the absence of 
enteric symptoms. Neurological abnormalities found in these 2 cohorts were 
heterogeneous and felt to be chance associations. No cases of gluten ataxia 
were seen nor was there any other evidence of gluten-induced immune-
mediated neurological damage. 
Whilst enteropathy in classical CD is presumed to be immune-mediated, 
gluten neurotoxicity via immune mechanisms remains unproven. The fourth 
study, described in Chapter 6, thus investigated the DH and CD cohorts for 
the presence of anti-neuronal antibodies using Western blotting. A novel 
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antibody was identified from peripheral blood in over 50% of the subjects with 
DH. This reacted with a protein of 74 kDa from an extract of human spinal 
cord. This antibody possibly suggests a potential mechanism for sensory 
ataxia, which has been previously described in patients with established 
gluten sensitivity. However none of the patients had clinical evidence of dorsal 
column dysfunction, which may indicate that an additional co-factor (possibly 
a trace vitamin) is required for the development of symptoms. The absence of 
this spinal cord antibody in patients with CD may reflect greater gluten 
exposure in DH patients who often continue to consume gluten as their 
dermatological symptoms may be controlled by dapsone alone.  
In the fifth study, described in Chapter 7, screening of 49 unselected MS 
cases for serological evidence of CD revealed IgA anti-endomysial antibody 
found in one case (2%). IgG AGA was found in 12% of patients and 13% of 
blood donors. This demonstrated the poor specificity of AGA (especially of 
IgG isotype) in a cohort of neurological patients the majority of whom did not 
have gluten sensitive disease. 
In the final study, presented in Chapter 8, AGA was compared with other food 
antibodies, and with the highly disease specific (IgA) anti-TTG in patients with 
LGLRSDWKLF DWD[LD DQG QHXURSDWK\ $OO IRRG DQWLERGLHV ZKHDW JOLDGLQ KHQV¶
HJJ RYDOEXPLQ DQG FRZV¶ PLON ODFWRJOREXOLQ SDUWLFXODUO\ RI ,J* W\SH ZHUH
found to be common in patients with idiopathic ataxia and neuropathy. None 
of the ataxia or neuropathy cases were positive for IgA anti-TTG making 
occult coeliac disease unlikely. HLA DQw2 was found distributed equally 
across all subject groups. DQw2 expressing, AGA positive cases were very 
rare in these clinics. This suggests that CD per se is not commonly associated 
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with either idiopathic ataxia or idiopathic neuropathy. I was unable to confirm 
that HLA DQw2 is commoner in cases of idiopathic ataxia or peripheral 
neuropathy. All food antibodies were more commonly found in these idiopathic 
cases, raising the question of abnormal gut permeability or gut inflammation 
or a non-specific age-related effect. 
9.2 Limitations 
Patient numbers were relatively small and thus the current study may not 
have been adequately powered to show the effects. No analysis was made of 
variables such as sex, co-morbidity, drugs, smoking etc. This work was 
retrospective and the prospective effect of treatment i.e. GFD was not 
assessed. Case series were liable both to under-reporting and over-reporting 
of neurological disorder. 
 
9.3 Merits 
The strength of this work was that this was neurologist-led with close 
collaboration with colleagues in numerous specialities namely 
gastroenterology, immunology, dermatology, neuroimmunology and 
epidemiology. It thus aims to present a holistic and scientifically sound 
impression of the nature of the association between gluten sensitivity and 
neurological disease. 
 
9.4 Recommendations 
Firstly, I would recommend more carefully-considered, stringent antibody 
testing in neurological patients given the poor predictive value of some coeliac 
antibodies particularly IgG AGA. Secondly, immunologists should be 
encouraged to provide well-defined, reproducible diagnostic tests and for 
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these to be universally adopted amongst neurologists as a more acceptable 
marker of gluten sensitivity. It may be that TTG or its successor will be this 
test. Finally, more detailed investigation is required. Interpretation of 
population-based studies is difficult because occult sub-clinical CD occurs 
commonly and background prevalence needs to be accounted for. The 
inadequacy of previous studies from a methodological viewpoint needs to be 
addressed in future work on this subject. I suggest that this requires inter-
disciplinary collaboration between neurologists, immunologists, 
gastroenterologists, geneticists and probably, most importantly, 
epidemiologists. 
9.5 Areas for future study 
Future studies would be increasingly powered by having large patient 
numbers, long term follow-up and possibly national or multinational registries 
of patients. Further large studies are required looking for the prevalence of 
neurological conditions in CD and DH, the role of auto-immunity, particularly in 
susceptible HLA groups, in neurological diseases seen with CD.  
 Randomised, controlled trials for treatment efficacy would be practically 
difficult. Studies with animal models of CD may provide important insights and 
this is certainly an exciting area for real-time study of this disease process in 
carefully controlled environments.  
9.5.1 Epilepsy and coeliac disease 
Whilst I have shown that a causative relationship between epilepsy and CD 
appears less likely, further study is recommended e.g. in the form of a case-
control study to determine firstly a consistent observed association and 
secondly to demonstrate a plausible scientific link. It may be that certain 
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groups of patients are at increased risk such as patients with significant folate 
deficiency. Furthermore, even if no actual association exists, it would be 
important to identify a treatable cause of malabsorption because of potentially 
impaired drug absorption. 
9.5.2 Ataxia and coeliac disease 
More in-depth study is required into the intriguing association of gliadin 
positivity with ataxia (both idiopathic and hereditary). Ataxia, be it sensory or 
cerebellar, idiopathic or hereditary, has been widely investigated. However 
many questions still remain. This research has raised the possibility of an anti-
spinal antibody which may contribute to the aetiology of a sensory ataxia. 
Positive gliadin antibodies, which are an unsatisfactory test in terms of 
sensitivity and specificity, are an intriguing and as yet unexplained finding. 
The presence of these in both hereditary and idiopathic cerebellar ataxias 
suggests a possible inflammatory aetiology. However it is well-known that 
these antibodies are raised in other autoimmune conditions such as diabetes 
and hypothyroidism. As such further study into the importance of this finding 
may prove to be fruitless. It may be of greater worth to accept that cerebellar 
ataxia has an inflammatory basis and direct further study towards exploring 
this mechanism from a different angle. 
9.5.3 The role of trace elements 
The neurological complications of CD, and indeed other enteric disease 
causing malabsorption, is a fascinating area for study as malabsorption may 
yet be proven to be of greater significance in this association than was 
previously realised. Although vitamin deficiency does not satisfactorily explain 
patients in whom no vitamin deficiency is found (Ward, Murphy et al. 1985; Lu, 
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Thompson et al. 1986) or in whom vitamin replacement has no effect (Bhatia, 
Brown et al. 1995), this possibility should still be carefully considered in CD 
patients who develop neurological illness. Whilst the role of some vitamins 
has been well-researched and well-documented, the role of numerous others 
is less clearly understood and moreover testing for these is often not routinely 
available. As yet, no studies have effectively addressed the role of trace 
vitamin deficiency (e.g. niacin, riboflavin and thiamine) in the development of 
neurological complications.  
9.5.4 Ongoing research generated by this study 
As demonstrated in part of this thesis, use of such databases such as the 
Coeliac Register set up by Dr Holmes in Derby, spanning many years and 
including large numbers of patients, is also an extremely informative source 
albeit flawed by potential observer bias. The General Practice Research 
Database (GPRD) is a computerised database of anonymised patient 
information obtained from General Practitioners including demographics, 
medical diagnosis, prescriptions, referrals etc. Data is contributed by 
numerous GP practices in the UK and currently consists of information on 
approximately 3 million patients (approximately 5% of the UK population). 
Collaboration is ongoing with colleagues in the Public Health Department at 
Nottingham University to examine the GPRD to carry out a historical cohort 
study. 
I aim to carry out further characterisation of the spinal antibody found in the 
DH cohort. Early immunohistochemical data suggests binding to dorsal 
column neurones from serum of these patients however this finding requires 
further confirmation. 
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9.5.5 Ongoing research worldwide 
Outcome of the NINDS study (which is currently recruiting patients) will be of 
great interest (http://clinicaltrials.gov). The investigators aim to screen patients 
with cerebellar ataxia for evidence of gluten sensitivity. Those with positive 
antibodies will then be commenced on GFD and monitored 3 monthly for 12 
months both for compliance to GFD and evaluation of ataxia. This is an open 
label controlled trial of GFD in patients with gluten sensitivity and cerebellar 
ataxia. Their controls will be patients with genetically-confirmed cerebellar 
ataxia e.g. SCA 1, 2, 3, 6, 7 DQG)ULHGULFK¶VDWD[LDRUFHUHEHOODUataxia from 
any other known cause e.g. alcohol, cerebrovascular disease). They also aim 
to have age and sex-matched normal subjects. 
 
9.6 Interpretation of results 
9.6.1 No evidence for gluten neurotoxicity 
The notion of gluten being neurotoxic is an attractive one. A GFD is a 
relatively simple and seemingly inexpensive treatment option. Moreover, with 
increased ease of screening for CD, the diagnosis would appear to be 
relatively straightforward. However the current study found no evidence to 
support the hypothesis that gluten sensitive enteropathy occurs with any 
greater frequency in patients with idiopathic neurological syndromes, namely 
multiple sclerosis, ataxia and neuropathy.  
It must firstly be stressed that associations do not prove causality and 
attributing a cure for patients with so-called gluten-related neurological illness 
may be detrimental. From an individual point of view, a strict GFD may be 
unpleasant and troublesome. Coeliac patients with few or no symptoms 
identified through screening will have to accept the burden of life-long 
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treatment in return for ill-defined benefits. Overall patients with CD have a 
two-fold increase in mortality compared to the general population (Logan, 
Rifkind et al. 1989). However, prognosis in patients who are asymptomatic is 
not known. Moreover there is a body of evidence that suggests some 
protective effects of CD in terms of lower mortality from cardiovascular 
disease, lower blood pressure and cholesterol levels than the general 
population (Green and Wollaeger 1960; Vuoristo and Miettinen 1985). 
Our understanding of autoimmune pathogenesis and the contribution of 
genetic and environmental factors is limited. We are still in an embryonic 
phase of understanding antineuronal pathology. Whilst we assume that 
antineuronal antibodies are pathogenic this has still not been robustly proven 
(although passive transfer of antibodies does induce disease features and 
reduction of antibody titres is often therapeutic). Genetic mechanisms of 
pathogenesis are also incompletely understood. It is far more likely that the 
neurological complications of CD are a combination of disease processes 
which may have the commonality of a single antibody (AGA) on serological 
testing as an epiphenomenon rather than a causative factor.  
9.6.2 Gluten ataxia not analogous to dermatitis herpetiformis 
,WKDVEHHQFODLPHGWKDW³JOXWHQDWD[LDLVDPDQLIHVWDtion of gluten sensitivity 
« DQDORJRXV WR WKH H[DPSOH RI GHUPDWLWLV KHUSHWLIRUPLV IURP ZKLFK LW LV
DSSDUHQW WKDW WKH JXW LV QRW WKH VROH SURWDJRQLVW LQ WKLV GLVHDVH´
(Hadjivassiliou, Grunewald et al. 2003). However AGA seropositivity does not 
equate to gluten sensitivity, a term that should be reserved for cases in which 
there is unequivocal, objective evidence of benefit with a GFD.  
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Using DH as typifying a gluten-sensitive illness in which a non-gastrointestinal 
syndrome predominates is problematic. Gluten ataxia and DH are not 
analogous in this regard. Although less than 10% of DH patients have 
gastrointestinal symptoms, they are all said to have a gluten-sensitive 
enteropathy (Reunala 1998). Patients with a genetic susceptibility to gluten 
may have no intestinal abnormalities on small bowel biopsy but true latent CD 
is uncommon.  
DH and CD are both strongly-associated with HLA DQ and with no genetic 
differences to explain the 2 phenotypes. DH is not fully understood but what 
evidence exists suggests precipitates of IgA in the papillary dermis containing 
epidermal transglutaminase.  Epidermal and tissue transglutaminases in DH 
and |CD respectively are highly homologous. Cross-reactivity of the two 
antibodies may explain why patients with either DH or CD will have antibodies 
to both these enzymes but in DH the skin manifestation occurs because 
epidermal transglutaminase antibodies produced are of high avidity and 
affinity (Karpati 2004). DH is a very specific disease process with very 
specific, increasingly better-characterised immune mechanisms, none of 
ZKLFKDUHUREXVWO\GHPRQVWUDWHGLQµJOXWHQDWD[LD¶ 
 
9.6.3 Is screening worthwhile? 
The criteria for mass screening are: a potentially serious condition with 
significant morbidity, difficult early clinical detection, availability of a sensitive, 
simple and cheap screening test and availability of an effective therapy. There 
is insufficient evidence to support mass screening for gluten sensitivity in 
unselected patient groups because uncertainty remains regarding the natural 
history of the disease. Specifically we need a clearer understanding of the 
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outcome in affected individuals who are essentially asymptomatic. Knowledge 
of lead-time duration (interval between detection and time at which diagnosis 
would have been made without screening) is crucial to rationalise the need for 
screening. At present, coeliac specialists advocate case finding i.e. remaining 
alert to the possibility of this diagnosis in patients with suggestive signs, 
symptoms or haematological/biochemical indices.  
On the basis of the available literature and work derived from this thesis, 
routine screening for gluten sensitivity in patients with neurological illness is 
not recommended unless there are signs and symptoms to suggest an 
underlying diagnosis. However, clinicians should remain vigilant for 
malabsorption which is potentially treatable and carry out careful screening for 
deficiency of vitamins and trace elements in patients known to have CD who 
present with neurological disease.  
 
9.7 Conclusion 
Disease reporting both from local experience as well as nationally has not 
suggested an association between gluten sensitivity and neurological disease. 
This research found no evidence of excessive neurological complications in 
patients with gluten sensitivity (DH and CD), nor evidence of increased gluten 
sensitivity in patients with neurological illness. One intriguing finding has been 
the demonstration of a novel anti-spinal antibody the significance of which 
remains to be determined. One further important finding demonstrated was 
that AGA (particularly of IgG isotype) is flawed by poor sensitivity, specificity 
and predictive value. 
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There continue to be conflicting reports regarding the nature of the association 
between gluten sensitivity and neurological disease. This work does not 
support this association. AGA positivity occurs in numerous neurological 
conditions but this does not equate with gluten neurotoxicity. The role of 
gliadin antibodies in neurological disease warrants further investigation. In 
view of the ongoing controversy, we must await further, scientifically-robust 
data to clarify this issue. However, it is hoped that this research has 
contributed to the interpretation of clinical and immunological data with regard 
to patients with neurological disease and possible gluten sensitivity. 
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